USA: +1 312-376-8303
EU: +44 208-144-9523
info@cognitivemarketresearch.com
D&B D-U-N-S No : 85-356-3074
Home Pharma & Healthcare Psychedelic Therapeutics Market

Psychedelic Therapeutics Market Report 2023 (Global Edition)

Companies: Celon Pharma Sa, Maps Public Benefit, Mindmed, Janssen Pharmaceuticals, Ix Biopharma Ltd, Jazz Pharmaceutical, Avadel, Pharmaceuticals Plc, Neurorx Inc, Douglas Pharmaceuticals Limited, The Emmes, Company Llc, Caamtech, Compass Pathways Plc, Eleusis Benefit Corporation, Awakn Life Sciences Inc, Psilera Bioscience, Braxia Scientific Corp, Mindset Pharma, Betterlife Pharma, Cybin, Cb Therapeutics, Numinus Wellness, Mydecine Innovations Group, Optimi Health, Pharmather, Field Trip Health, Atai Life Sciences, Gh Research, Seelos Therapeutics, Small Pharma, Bright Minds Biosciences Incannex Health, Psybio Therapeutics, Universal Ibogaine, Levitee Labs, Mind Cure Health, Novamind, Clearmind Medicine, Mynd Life Science, Wesana Health, Psyched Wellness, Havn Life Sciences, Tryp Therapeutics, Psyence Group, Silo Pharma, Core One Labs, M2Bio Sciences, Neonmind Biosciences, Delic Corp, Nova Mentis Life Science, Beckley Psytech, Delix Therapeutics, Diamond Therapeutics, Tactogen, Psygen Labs Inc, Bexson Biomedical, Eleusis Biotech, Psilera Biosceince, Octarine Bio, Heading Health, Maps Public Benefit Corporation (Pbc), Aphrodite Health, Terran Biosciences, Mycrodose Therapeutics, Reset Pharma, Clerkenwell Health, Alvarius Pharmaceuticals, Ceruvia Lifesciences
Type: GHB, Ketamine, MDMA, Psilocybin, DMT, Ayahuasca, LSD, Other

Origin of Psychedelic Substance:

 Synthetic Substances, Natural Substances
Target Therapeutic Area: Depression and Anxiety Disorders, Pain Disorders, Sleep-Related Disorders, Trauma, Other

The base year for the calculation is 2023 and 2018 to 2022 will be historical period. The year 2023 will be estimated one while the forecasted data will be from year 2023 to 2028. When we deliver the report that time we updated report data till the purchase date.

     CMR744915     250+    

PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.

PDF | PPT | Excel | Word | Bi      4.6     3
COVID-19 Impact and Post Recovery Analysis for Psychedelic Therapeutics Market Report Edition, Data Updated till April 2023 (7th Edition) | Discount Offers Upto 30% + Complimentary Report Access with 3 years Subscription!

Share your contact details to receive free updated sample copy/pages of the recently published edition of Psychedelic Therapeutics Market Report 2023.

Key Insights from Psychedelic Therapeutics Market Report

"Global Psychedelic Therapeutics market size 2022 was XX Million. Psychedelic Therapeutics Industry compound annual growth rate (CAGR) will be XX% from 2023 till 2030."

Psychedelic Therapeutics Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!

Psychedelic Therapeutics Market Report Description

Cognitive Market Research has recently published the 7th edition of Psychedelic Therapeutics Market Report 2023. It provides majorly two types of information qualitative and quantitative. In terms of quantitative data, current market size, competitors market shares, market forecast, and other industry updates with respect to global, regional, and country levels. Whereas qualitative data, unveils market drivers, restraints, current trends, opportunities, and more. To know more, we encourage you to order the free sample pages.

Market Dynamics such as Drivers, Restraints, Opportunities, Trends data

Psychedelic Therapeutics Industry Dynamics

  • Market Drivers of Psychedelic Therapeutics: The key factors which influence the overall sales demand for Psychedelic Therapeutics Industry in a positive way. Market drivers help you understand the impact on market growth. With this information you can predict how said market is likely to grow in the coming year. 
  • Market Restraints of Psychedelic Therapeutics: Restraints are the negative factors which hinder the market growth and development in the near future. Some of the restraining factors including strict government regulations, supply chain disruptions, changing consumer preference are affecting the market growth in the near future. For example, the outburst of COVID-19 affected the most of the industries. Restraining factors are important to analyse on account of companies can develop strategies to overcome their negative impact on the growth of the market.
  • Market Opportunities of Psychedelic Therapeutics: Market opportunities are expected to open up growth window for the new entrants in the market. It helps to understand unmet needs or an untapped potential in the market.
  • Market Trends of Psychedelic Therapeutics: (This information will be part of the paid report version.)

Timelines can be altered (extra years data or less years data) as per the data needs

Report Timeline and Details
Base Year2022
Historical Data Time Period2018-2022
Forecast Period2023-2030
Report Edition7th Edition (2023)
Last UpdateLast Updated In April 2023
Next Report Edition June 2023 (Pre-Booking Available)
Market Forecast/Projection Time Period2023-2030
Report Format PDF | PPT | Excel | Word | Bi
Report IDCMR744915

Psychedelic Therapeutics Market Report 2023 (Global Edition) Table of Content differs according to the user License selection. Current Displayed TOC is for the Single User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report. Specific section/s of report can be ordered at a discounted price. If applicable; On Request Volume Data will also be provided (at an Additional Cost).

Table of Content (Revenue USD Edition), (Enquire about Volume/Consumption Edition Data)

This chapter helps you to understand the importance of report and how we designed the report scope of Psychedelic Therapeutics market. As per your requirement we can also design the market scope as a customised report.

Chapter 1 Industrial Insight and Market Scope
  • 1.1 Global Psychedelic Therapeutics Industry Introduction
  • 1.2 Objectives of the Study
  • 1.3 USP of the Report
  • 1.4 Who is this report for?
  • 1.5 Designing of Market Scope
    • 1.5.1 Psychedelic Therapeutics Market Segmentation
    • 1.5.1 Psychedelic Therapeutics Market Regional Fragmentation
    • 1.5.1 Psychedelic Therapeutics Market Players
  • 1.6 Report Duration
  • 1.7 List of Stakeholders

This chapter provides insights on our data collection and data validation process. It covers detailed information on wide range of sources referred during the study.

Chapter 2 Research MethodologyReview Complete Research Methodology
  • 2.1 Psychedelic Therapeutics Market Report 2023 Research Methodology
  • 2.2 Systematic Research Approach
    • 2.2.1 Primary Research
      • 2.2.1.1 Key Data from Primary
      • 2.2.1.2 Primary Interviews with Experts
      • 2.2.1.3 Key Industry Insights
      • 2.2.1.4 Questionnaire

        At Cognitive Market Research, we have designed questionnaire focused on Psychedelic Therapeutics Market for the statistical study. This questionnaire is the key part of our research methodology which is shared with number of Psychedelic Therapeutics industry experts of entire value chain, located across the globe. This study help us to gather accurate quantitative and qualitative data for the final report.

      • 2.2.1.5 Breakdown of Primaries
    • 2.2.2 Secondary Research
      • 2.2.2.1 Key Data from Secondary
      • 2.2.2.2 Paid Sources
      • 2.2.2.3 Public Sources
  • 2.3 Market Size Estimation
    • 2.3.1 Top-Down Approach
      • 2.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
    • 2.3.1 Bottom-UP Approach
      • 2.3.1.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
  • 2.4 Market Breakdown and Data Triangulation
  • 2.5 Research Assumptions

The executive summary is an overview of a Psychedelic Therapeutics Market Report. In this chapter we have summarized the overall report data in snapshot format.

Chapter 3 Executive Summary of Psychedelic Therapeutics Market
  • 3.1 Global Psychedelic Therapeutics Market Size 2018 – 2030, (USD Million)
  • 3.2 Global Psychedelic Therapeutics Value, Absolute & Opportunity Analysis
  • 3.3 Global Psychedelic Therapeutics Market Y-o-Y Growth Rate Projection by Region (2023 - 2030)
  • 3.4 Global Psychedelic Therapeutics Market Statistics 2022: Snapshot

This chapters incorporated product description overview and regional sales statistics for the year 2018-2030.

Chapter 4 Global Psychedelic Therapeutics Market Overview
  • 4.1 Psychedelic Therapeutics Introduction
  • 4.2 Global Psychedelic Therapeutics Market Statistics by Regions (2018-2030)
    • 4.2.1 North America Psychedelic Therapeutics Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
    • 4.2.2 Europe Psychedelic Therapeutics Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
    • 4.2.3 Asia Pacific Psychedelic Therapeutics Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
    • 4.2.4 Latin America Psychedelic Therapeutics Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
    • 4.2.5 Middle East and Africa Psychedelic Therapeutics Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
  • 4.3 Global Psychedelic Therapeutics Market Size (2018-2030)
    • 4.3.1 Global Psychedelic Therapeutics Revenue Status and Outlook (2018-2030)
  • 4.4 Global Psychedelic Therapeutics Market Price Analysis by Regions (2018-2030)

This chapter covers a competitive analysis of the global Psychedelic Therapeutics market, and it includes quantitative information such as revenue and market share of the manufacturers. The chapter also includes information regarding the strategies adopted by the manufacturers such as mergers, acquisitions, and new product launches.

Chapter 5 Competitive Analysis (Subject to Availability)
  • 5.1 Global Psychedelic Therapeutics Market Revenue and Share by Manufacturers (2018-2022)
  • 5.2 Global Psychedelic Therapeutics Industry Mergers and Acquisition Analysis
  • 5.3 Global Psychedelic Therapeutics New Launches Analysis
  • 5.4 Company Categorization
  • 5.5 Global Psychedelic Therapeutics Top Winning Strategies, by Manufacturers (2018-2022)

ESG analysis is the consideration of all factors in investment including environmental, social, and governance (ESG) factors. ESG integration is key part of the investment process. ESG analysis helps to measure company’s goals and progress when it comes to climate change, social improvement and good governance.

Chapter 6 Environmental, Social, and Governance (ESG) Analysis
  • 6.1 Overall Company’s Disclosure Score

This chapter helps you understand the Market Drivers, Market Restrain, Market Opportunity and Trends by each segment.

Chapter 7 Qualitative Analysis
  • 7.1 Psychedelic Therapeutics Industrial Dynamics
    • 7.1.1 Global Psychedelic Therapeutics Market Drivers
    • 7.1.2 Global Psychedelic Therapeutics Market Restrains
    • 7.1.3 Global Psychedelic Therapeutics Market Opportunities
    • 7.1.4 Global Psychedelic Therapeutics Market Trends
  • 7.2 Psychedelic Therapeutics Market Attractiveness Analysis
    • 7.1.1 Market Attractiveness Analysis by Type Segment
    • 7.1.2 Market Attractiveness Analysis by Application Segment
  • 7.3 PESTEL Analysis for Psychedelic Therapeutics Market
    • 7.3.1 Political Factors
    • 7.3.2 Economic Factors
    • 7.3.3 Social Factors
    • 7.3.4 Technological Factors
    • 7.3.5 Legal Factors
    • 7.3.6 Environmental Factors
  • 7.4 Porter’s Five Forces Analysis for Psychedelic Therapeutics Market
    • 7.4.1 Bargaining Power of Suppliers
    • 7.4.2 Bargaining Power of Buyers
    • 7.4.3 Threat of Substitutes
    • 7.4.4 Threat of New Entrants
    • 7.4.5 Degree of Competition
  • 7.5 COVID-19 Impact on Psychedelic Therapeutics Industry
    • 7.4.1 Overall Impact of COVID-19 on Psychedelic Therapeutics Industry
    • 7.4.2 Post COVID-19 Impact and Recovery Analysis
    • 7.4.3 Influencing Factors
  • 7.6 Consumer Preference Analysis for Psychedelic Therapeutics Market
  • 7.7 Patent Analysis of Psychedelic Therapeutics
  • 7.8 Psychedelic Therapeutics Industrial Chain Analysis
  • 7.9 Manufacturing Cost Analysis

This segment of the report provides in-depth and pertinent information on every foremost player in the market through both primary and secondary research. The Company Basic Information, and Sales Area chapter includes ten or more key players, which are dominating the market. Each company profile includes demystifying professional information in a tabular format, which comprises the company’s official website, established year, market position, geographical presence, competitors, and contact information. Further, company profiling includes an in-detailed business overview, COVID-19 impact on the particular firm, product type specifications, revenue & market share, and recent developments done by the company for its inorganic development, such as mergers, strategic acquisitions, partnerships, and others. Besides, profiling includes the company’s investment in research and development activities. The recent innovative product launches, business expansion, investments done by the company in different markets, and other news are also available in the company profiling section. At last, it provides the company’s business strategy and SWOT analysis.

Chapter 8 Company Profiling (Subject to Availability)
  • 8.1 Celon Pharma Sa
    • 8.1.1 Celon Pharma Sa Company Basic Information, and Sales Area
    • 8.1.2 Celon Pharma Sa Business Segment/ Overview
    • 8.1.3 Celon Pharma Sa Financials
      • 8.1.3.1 Investment in Research and Development
      • 8.1.3.2 Celon Pharma Sa Sales Revenue (2018-2022)
      • 8.1.3.3 Celon Pharma Sa Market Share (2018-2022)
    • 8.1.4 Celon Pharma Sa Recent Developments
    • 8.1.5 Celon Pharma Sa Business Strategy
    • 8.1.6 Celon Pharma Sa Management Change
    • 8.1.7 Celon Pharma Sa SWOT Analysis
      • 8.1.7.1 Strength
      • 8.1.7.2 Weakness
      • 8.1.7.3 Opportunity
      • 8.1.7.4 Threats
    • 8.1.8 Celon Pharma Sa COVID-19 Impact Analysis
  • 8.2 Maps Public Benefit
    • 8.2.1 Maps Public Benefit Company Basic Information, and Sales Area
    • 8.2.2 Maps Public Benefit Business Segment/ Overview
    • 8.2.3 Maps Public Benefit Financials
      • 8.2.3.1 Investment in Research and Development
      • 8.2.3.2 Maps Public Benefit Sales Revenue (2018-2022)
      • 8.2.3.3 Maps Public Benefit Market Share (2018-2022)
    • 8.2.4 Maps Public Benefit Recent Developments
    • 8.2.5 Maps Public Benefit Business Strategy
    • 8.2.6 Maps Public Benefit Management Change
    • 8.2.7 Maps Public Benefit SWOT Analysis
      • 8.2.7.1 Strength
      • 8.2.7.2 Weakness
      • 8.2.7.3 Opportunity
      • 8.2.7.4 Threats
    • 8.2.8 Maps Public Benefit COVID-19 Impact Analysis
  • 8.3 Mindmed
    • 8.3.1 Mindmed Company Basic Information, and Sales Area
    • 8.3.2 Mindmed Business Segment/ Overview
    • 8.3.3 Mindmed Financials
      • 8.3.3.1 Investment in Research and Development
      • 8.3.3.2 Mindmed Sales Revenue (2018-2022)
      • 8.3.3.3 Mindmed Market Share (2018-2022)
    • 8.3.4 Mindmed Recent Developments
    • 8.3.5 Mindmed Business Strategy
    • 8.3.6 Mindmed Management Change
    • 8.3.7 Mindmed SWOT Analysis
      • 8.3.7.1 Strength
      • 8.3.7.2 Weakness
      • 8.3.7.3 Opportunity
      • 8.3.7.4 Threats
    • 8.3.8 Mindmed COVID-19 Impact Analysis
  • 8.4 Janssen Pharmaceuticals
    • 8.4.1 Janssen Pharmaceuticals Company Basic Information, and Sales Area
    • 8.4.2 Janssen Pharmaceuticals Business Segment/ Overview
    • 8.4.3 Janssen Pharmaceuticals Financials
      • 8.4.3.1 Investment in Research and Development
      • 8.4.3.2 Janssen Pharmaceuticals Sales Revenue (2018-2022)
      • 8.4.3.3 Janssen Pharmaceuticals Market Share (2018-2022)
    • 8.4.4 Janssen Pharmaceuticals Recent Developments
    • 8.4.5 Janssen Pharmaceuticals Business Strategy
    • 8.4.6 Janssen Pharmaceuticals Management Change
    • 8.4.7 Janssen Pharmaceuticals SWOT Analysis
      • 8.4.7.1 Strength
      • 8.4.7.2 Weakness
      • 8.4.7.3 Opportunity
      • 8.4.7.4 Threats
    • 8.4.8 Janssen Pharmaceuticals COVID-19 Impact Analysis
  • 8.5 Ix Biopharma Ltd
    • 8.5.1 Ix Biopharma Ltd Company Basic Information, and Sales Area
    • 8.5.2 Ix Biopharma Ltd Business Segment/ Overview
    • 8.5.3 Ix Biopharma Ltd Financials
      • 8.5.3.1 Investment in Research and Development
      • 8.5.3.2 Ix Biopharma Ltd Sales Revenue (2018-2022)
      • 8.5.3.3 Ix Biopharma Ltd Market Share (2018-2022)
    • 8.5.4 Ix Biopharma Ltd Recent Developments
    • 8.5.5 Ix Biopharma Ltd Business Strategy
    • 8.5.6 Ix Biopharma Ltd Management Change
    • 8.5.7 Ix Biopharma Ltd SWOT Analysis
      • 8.5.7.1 Strength
      • 8.5.7.2 Weakness
      • 8.5.7.3 Opportunity
      • 8.5.7.4 Threats
    • 8.5.8 Ix Biopharma Ltd COVID-19 Impact Analysis
  • 8.6 Jazz Pharmaceutical
    • 8.6.1 Jazz Pharmaceutical Company Basic Information, and Sales Area
    • 8.6.2 Jazz Pharmaceutical Business Segment/ Overview
    • 8.6.3 Jazz Pharmaceutical Financials
      • 8.6.3.1 Investment in Research and Development
      • 8.6.3.2 Jazz Pharmaceutical Sales Revenue (2018-2022)
      • 8.6.3.3 Jazz Pharmaceutical Market Share (2018-2022)
    • 8.6.4 Jazz Pharmaceutical Recent Developments
    • 8.6.5 Jazz Pharmaceutical Business Strategy
    • 8.6.6 Jazz Pharmaceutical Management Change
    • 8.6.7 Jazz Pharmaceutical SWOT Analysis
      • 8.6.7.1 Strength
      • 8.6.7.2 Weakness
      • 8.6.7.3 Opportunity
      • 8.6.7.4 Threats
    • 8.6.8 Jazz Pharmaceutical COVID-19 Impact Analysis
  • 8.7 Avadel
    • 8.7.1 Avadel Company Basic Information, and Sales Area
    • 8.7.2 Avadel Business Segment/ Overview
    • 8.7.3 Avadel Financials
      • 8.7.3.1 Investment in Research and Development
      • 8.7.3.2 Avadel Sales Revenue (2018-2022)
      • 8.7.3.3 Avadel Market Share (2018-2022)
    • 8.7.4 Avadel Recent Developments
    • 8.7.5 Avadel Business Strategy
    • 8.7.6 Avadel Management Change
    • 8.7.7 Avadel SWOT Analysis
      • 8.7.7.1 Strength
      • 8.7.7.2 Weakness
      • 8.7.7.3 Opportunity
      • 8.7.7.4 Threats
    • 8.7.8 Avadel COVID-19 Impact Analysis
  • 8.8 Pharmaceuticals Plc
    • 8.8.1 Pharmaceuticals Plc Company Basic Information, and Sales Area
    • 8.8.2 Pharmaceuticals Plc Business Segment/ Overview
    • 8.8.3 Pharmaceuticals Plc Financials
      • 8.8.3.1 Investment in Research and Development
      • 8.8.3.2 Pharmaceuticals Plc Sales Revenue (2018-2022)
      • 8.8.3.3 Pharmaceuticals Plc Market Share (2018-2022)
    • 8.8.4 Pharmaceuticals Plc Recent Developments
    • 8.8.5 Pharmaceuticals Plc Business Strategy
    • 8.8.6 Pharmaceuticals Plc Management Change
    • 8.8.7 Pharmaceuticals Plc SWOT Analysis
      • 8.8.7.1 Strength
      • 8.8.7.2 Weakness
      • 8.8.7.3 Opportunity
      • 8.8.7.4 Threats
    • 8.8.8 Pharmaceuticals Plc COVID-19 Impact Analysis
  • 8.9 Neurorx Inc
    • 8.9.1 Neurorx Inc Company Basic Information, and Sales Area
    • 8.9.2 Neurorx Inc Business Segment/ Overview
    • 8.9.3 Neurorx Inc Financials
      • 8.9.3.1 Investment in Research and Development
      • 8.9.3.2 Neurorx Inc Sales Revenue (2018-2022)
      • 8.9.3.3 Neurorx Inc Market Share (2018-2022)
    • 8.9.4 Neurorx Inc Recent Developments
    • 8.9.5 Neurorx Inc Business Strategy
    • 8.9.6 Neurorx Inc Management Change
    • 8.9.7 Neurorx Inc SWOT Analysis
      • 8.9.7.1 Strength
      • 8.9.7.2 Weakness
      • 8.9.7.3 Opportunity
      • 8.9.7.4 Threats
    • 8.9.8 Neurorx Inc COVID-19 Impact Analysis
  • 8.10 Douglas Pharmaceuticals Limited
    • 8.10.1 Douglas Pharmaceuticals Limited Company Basic Information, and Sales Area
    • 8.10.2 Douglas Pharmaceuticals Limited Business Segment/ Overview
    • 8.10.3 Douglas Pharmaceuticals Limited Financials
      • 8.10.3.1 Investment in Research and Development
      • 8.10.3.2 Douglas Pharmaceuticals Limited Sales Revenue (2018-2022)
      • 8.10.3.3 Douglas Pharmaceuticals Limited Market Share (2018-2022)
    • 8.10.4 Douglas Pharmaceuticals Limited Recent Developments
    • 8.10.5 Douglas Pharmaceuticals Limited Business Strategy
    • 8.10.6 Douglas Pharmaceuticals Limited Management Change
    • 8.10.7 Douglas Pharmaceuticals Limited SWOT Analysis
      • 8.10.7.1 Strength
      • 8.10.7.2 Weakness
      • 8.10.7.3 Opportunity
      • 8.10.7.4 Threats
    • 8.10.8 Douglas Pharmaceuticals Limited COVID-19 Impact Analysis
  • 8.11 The Emmes
    • 8.11.1 The Emmes Company Basic Information, and Sales Area
    • 8.11.2 The Emmes Business Segment/ Overview
    • 8.11.3 The Emmes Financials
      • 8.11.3.1 Investment in Research and Development
      • 8.11.3.2 The Emmes Sales Revenue (2018-2022)
      • 8.11.3.3 The Emmes Market Share (2018-2022)
    • 8.11.4 The Emmes Recent Developments
    • 8.11.5 The Emmes Business Strategy
    • 8.11.6 The Emmes Management Change
    • 8.11.7 The Emmes SWOT Analysis
      • 8.11.7.1 Strength
      • 8.11.7.2 Weakness
      • 8.11.7.3 Opportunity
      • 8.11.7.4 Threats
    • 8.11.8 The Emmes COVID-19 Impact Analysis
  • 8.12 Company Llc
    • 8.12.1 Company Llc Company Basic Information, and Sales Area
    • 8.12.2 Company Llc Business Segment/ Overview
    • 8.12.3 Company Llc Financials
      • 8.12.3.1 Investment in Research and Development
      • 8.12.3.2 Company Llc Sales Revenue (2018-2022)
      • 8.12.3.3 Company Llc Market Share (2018-2022)
    • 8.12.4 Company Llc Recent Developments
    • 8.12.5 Company Llc Business Strategy
    • 8.12.6 Company Llc Management Change
    • 8.12.7 Company Llc SWOT Analysis
      • 8.12.7.1 Strength
      • 8.12.7.2 Weakness
      • 8.12.7.3 Opportunity
      • 8.12.7.4 Threats
    • 8.12.8 Company Llc COVID-19 Impact Analysis
  • 8.13 Caamtech
    • 8.13.1 Caamtech Company Basic Information, and Sales Area
    • 8.13.2 Caamtech Business Segment/ Overview
    • 8.13.3 Caamtech Financials
      • 8.13.3.1 Investment in Research and Development
      • 8.13.3.2 Caamtech Sales Revenue (2018-2022)
      • 8.13.3.3 Caamtech Market Share (2018-2022)
    • 8.13.4 Caamtech Recent Developments
    • 8.13.5 Caamtech Business Strategy
    • 8.13.6 Caamtech Management Change
    • 8.13.7 Caamtech SWOT Analysis
      • 8.13.7.1 Strength
      • 8.13.7.2 Weakness
      • 8.13.7.3 Opportunity
      • 8.13.7.4 Threats
    • 8.13.8 Caamtech COVID-19 Impact Analysis
  • 8.14 Compass Pathways Plc
    • 8.14.1 Compass Pathways Plc Company Basic Information, and Sales Area
    • 8.14.2 Compass Pathways Plc Business Segment/ Overview
    • 8.14.3 Compass Pathways Plc Financials
      • 8.14.3.1 Investment in Research and Development
      • 8.14.3.2 Compass Pathways Plc Sales Revenue (2018-2022)
      • 8.14.3.3 Compass Pathways Plc Market Share (2018-2022)
    • 8.14.4 Compass Pathways Plc Recent Developments
    • 8.14.5 Compass Pathways Plc Business Strategy
    • 8.14.6 Compass Pathways Plc Management Change
    • 8.14.7 Compass Pathways Plc SWOT Analysis
      • 8.14.7.1 Strength
      • 8.14.7.2 Weakness
      • 8.14.7.3 Opportunity
      • 8.14.7.4 Threats
    • 8.14.8 Compass Pathways Plc COVID-19 Impact Analysis
  • 8.15 Eleusis Benefit Corporation
    • 8.15.1 Eleusis Benefit Corporation Company Basic Information, and Sales Area
    • 8.15.2 Eleusis Benefit Corporation Business Segment/ Overview
    • 8.15.3 Eleusis Benefit Corporation Financials
      • 8.15.3.1 Investment in Research and Development
      • 8.15.3.2 Eleusis Benefit Corporation Sales Revenue (2018-2022)
      • 8.15.3.3 Eleusis Benefit Corporation Market Share (2018-2022)
    • 8.15.4 Eleusis Benefit Corporation Recent Developments
    • 8.15.5 Eleusis Benefit Corporation Business Strategy
    • 8.15.6 Eleusis Benefit Corporation Management Change
    • 8.15.7 Eleusis Benefit Corporation SWOT Analysis
      • 8.15.7.1 Strength
      • 8.15.7.2 Weakness
      • 8.15.7.3 Opportunity
      • 8.15.7.4 Threats
    • 8.15.8 Eleusis Benefit Corporation COVID-19 Impact Analysis
  • 8.16 Awakn Life Sciences Inc
    • 8.16.1 Awakn Life Sciences Inc Company Basic Information, and Sales Area
    • 8.16.2 Awakn Life Sciences Inc Business Segment/ Overview
    • 8.16.3 Awakn Life Sciences Inc Financials
      • 8.16.3.1 Investment in Research and Development
      • 8.16.3.2 Awakn Life Sciences Inc Sales Revenue (2018-2022)
      • 8.16.3.3 Awakn Life Sciences Inc Market Share (2018-2022)
    • 8.16.4 Awakn Life Sciences Inc Recent Developments
    • 8.16.5 Awakn Life Sciences Inc Business Strategy
    • 8.16.6 Awakn Life Sciences Inc Management Change
    • 8.16.7 Awakn Life Sciences Inc SWOT Analysis
      • 8.16.7.1 Strength
      • 8.16.7.2 Weakness
      • 8.16.7.3 Opportunity
      • 8.16.7.4 Threats
    • 8.16.8 Awakn Life Sciences Inc COVID-19 Impact Analysis
  • 8.17 Psilera Bioscience
    • 8.17.1 Psilera Bioscience Company Basic Information, and Sales Area
    • 8.17.2 Psilera Bioscience Business Segment/ Overview
    • 8.17.3 Psilera Bioscience Financials
      • 8.17.3.1 Investment in Research and Development
      • 8.17.3.2 Psilera Bioscience Sales Revenue (2018-2022)
      • 8.17.3.3 Psilera Bioscience Market Share (2018-2022)
    • 8.17.4 Psilera Bioscience Recent Developments
    • 8.17.5 Psilera Bioscience Business Strategy
    • 8.17.6 Psilera Bioscience Management Change
    • 8.17.7 Psilera Bioscience SWOT Analysis
      • 8.17.7.1 Strength
      • 8.17.7.2 Weakness
      • 8.17.7.3 Opportunity
      • 8.17.7.4 Threats
    • 8.17.8 Psilera Bioscience COVID-19 Impact Analysis
  • 8.18 Braxia Scientific Corp
    • 8.18.1 Braxia Scientific Corp Company Basic Information, and Sales Area
    • 8.18.2 Braxia Scientific Corp Business Segment/ Overview
    • 8.18.3 Braxia Scientific Corp Financials
      • 8.18.3.1 Investment in Research and Development
      • 8.18.3.2 Braxia Scientific Corp Sales Revenue (2018-2022)
      • 8.18.3.3 Braxia Scientific Corp Market Share (2018-2022)
    • 8.18.4 Braxia Scientific Corp Recent Developments
    • 8.18.5 Braxia Scientific Corp Business Strategy
    • 8.18.6 Braxia Scientific Corp Management Change
    • 8.18.7 Braxia Scientific Corp SWOT Analysis
      • 8.18.7.1 Strength
      • 8.18.7.2 Weakness
      • 8.18.7.3 Opportunity
      • 8.18.7.4 Threats
    • 8.18.8 Braxia Scientific Corp COVID-19 Impact Analysis
  • 8.19 Mindset Pharma
    • 8.19.1 Mindset Pharma Company Basic Information, and Sales Area
    • 8.19.2 Mindset Pharma Business Segment/ Overview
    • 8.19.3 Mindset Pharma Financials
      • 8.19.3.1 Investment in Research and Development
      • 8.19.3.2 Mindset Pharma Sales Revenue (2018-2022)
      • 8.19.3.3 Mindset Pharma Market Share (2018-2022)
    • 8.19.4 Mindset Pharma Recent Developments
    • 8.19.5 Mindset Pharma Business Strategy
    • 8.19.6 Mindset Pharma Management Change
    • 8.19.7 Mindset Pharma SWOT Analysis
      • 8.19.7.1 Strength
      • 8.19.7.2 Weakness
      • 8.19.7.3 Opportunity
      • 8.19.7.4 Threats
    • 8.19.8 Mindset Pharma COVID-19 Impact Analysis
  • 8.20 Betterlife Pharma
    • 8.20.1 Betterlife Pharma Company Basic Information, and Sales Area
    • 8.20.2 Betterlife Pharma Business Segment/ Overview
    • 8.20.3 Betterlife Pharma Financials
      • 8.20.3.1 Investment in Research and Development
      • 8.20.3.2 Betterlife Pharma Sales Revenue (2018-2022)
      • 8.20.3.3 Betterlife Pharma Market Share (2018-2022)
    • 8.20.4 Betterlife Pharma Recent Developments
    • 8.20.5 Betterlife Pharma Business Strategy
    • 8.20.6 Betterlife Pharma Management Change
    • 8.20.7 Betterlife Pharma SWOT Analysis
      • 8.20.7.1 Strength
      • 8.20.7.2 Weakness
      • 8.20.7.3 Opportunity
      • 8.20.7.4 Threats
    • 8.20.8 Betterlife Pharma COVID-19 Impact Analysis
  • 8.21 Cybin
    • 8.21.1 Cybin Company Basic Information, and Sales Area
    • 8.21.2 Cybin Business Segment/ Overview
    • 8.21.3 Cybin Financials
      • 8.21.3.1 Investment in Research and Development
      • 8.21.3.2 Cybin Sales Revenue (2018-2022)
      • 8.21.3.3 Cybin Market Share (2018-2022)
    • 8.21.4 Cybin Recent Developments
    • 8.21.5 Cybin Business Strategy
    • 8.21.6 Cybin Management Change
    • 8.21.7 Cybin SWOT Analysis
      • 8.21.7.1 Strength
      • 8.21.7.2 Weakness
      • 8.21.7.3 Opportunity
      • 8.21.7.4 Threats
    • 8.21.8 Cybin COVID-19 Impact Analysis
  • 8.22 Cb Therapeutics
    • 8.22.1 Cb Therapeutics Company Basic Information, and Sales Area
    • 8.22.2 Cb Therapeutics Business Segment/ Overview
    • 8.22.3 Cb Therapeutics Financials
      • 8.22.3.1 Investment in Research and Development
      • 8.22.3.2 Cb Therapeutics Sales Revenue (2018-2022)
      • 8.22.3.3 Cb Therapeutics Market Share (2018-2022)
    • 8.22.4 Cb Therapeutics Recent Developments
    • 8.22.5 Cb Therapeutics Business Strategy
    • 8.22.6 Cb Therapeutics Management Change
    • 8.22.7 Cb Therapeutics SWOT Analysis
      • 8.22.7.1 Strength
      • 8.22.7.2 Weakness
      • 8.22.7.3 Opportunity
      • 8.22.7.4 Threats
    • 8.22.8 Cb Therapeutics COVID-19 Impact Analysis
  • 8.23 Numinus Wellness
    • 8.23.1 Numinus Wellness Company Basic Information, and Sales Area
    • 8.23.2 Numinus Wellness Business Segment/ Overview
    • 8.23.3 Numinus Wellness Financials
      • 8.23.3.1 Investment in Research and Development
      • 8.23.3.2 Numinus Wellness Sales Revenue (2018-2022)
      • 8.23.3.3 Numinus Wellness Market Share (2018-2022)
    • 8.23.4 Numinus Wellness Recent Developments
    • 8.23.5 Numinus Wellness Business Strategy
    • 8.23.6 Numinus Wellness Management Change
    • 8.23.7 Numinus Wellness SWOT Analysis
      • 8.23.7.1 Strength
      • 8.23.7.2 Weakness
      • 8.23.7.3 Opportunity
      • 8.23.7.4 Threats
    • 8.23.8 Numinus Wellness COVID-19 Impact Analysis
  • 8.24 Mydecine Innovations Group
    • 8.24.1 Mydecine Innovations Group Company Basic Information, and Sales Area
    • 8.24.2 Mydecine Innovations Group Business Segment/ Overview
    • 8.24.3 Mydecine Innovations Group Financials
      • 8.24.3.1 Investment in Research and Development
      • 8.24.3.2 Mydecine Innovations Group Sales Revenue (2018-2022)
      • 8.24.3.3 Mydecine Innovations Group Market Share (2018-2022)
    • 8.24.4 Mydecine Innovations Group Recent Developments
    • 8.24.5 Mydecine Innovations Group Business Strategy
    • 8.24.6 Mydecine Innovations Group Management Change
    • 8.24.7 Mydecine Innovations Group SWOT Analysis
      • 8.24.7.1 Strength
      • 8.24.7.2 Weakness
      • 8.24.7.3 Opportunity
      • 8.24.7.4 Threats
    • 8.24.8 Mydecine Innovations Group COVID-19 Impact Analysis
  • 8.25 Optimi Health
    • 8.25.1 Optimi Health Company Basic Information, and Sales Area
    • 8.25.2 Optimi Health Business Segment/ Overview
    • 8.25.3 Optimi Health Financials
      • 8.25.3.1 Investment in Research and Development
      • 8.25.3.2 Optimi Health Sales Revenue (2018-2022)
      • 8.25.3.3 Optimi Health Market Share (2018-2022)
    • 8.25.4 Optimi Health Recent Developments
    • 8.25.5 Optimi Health Business Strategy
    • 8.25.6 Optimi Health Management Change
    • 8.25.7 Optimi Health SWOT Analysis
      • 8.25.7.1 Strength
      • 8.25.7.2 Weakness
      • 8.25.7.3 Opportunity
      • 8.25.7.4 Threats
    • 8.25.8 Optimi Health COVID-19 Impact Analysis
  • 8.26 Pharmather
    • 8.26.1 Pharmather Company Basic Information, and Sales Area
    • 8.26.2 Pharmather Business Segment/ Overview
    • 8.26.3 Pharmather Financials
      • 8.26.3.1 Investment in Research and Development
      • 8.26.3.2 Pharmather Sales Revenue (2018-2022)
      • 8.26.3.3 Pharmather Market Share (2018-2022)
    • 8.26.4 Pharmather Recent Developments
    • 8.26.5 Pharmather Business Strategy
    • 8.26.6 Pharmather Management Change
    • 8.26.7 Pharmather SWOT Analysis
      • 8.26.7.1 Strength
      • 8.26.7.2 Weakness
      • 8.26.7.3 Opportunity
      • 8.26.7.4 Threats
    • 8.26.8 Pharmather COVID-19 Impact Analysis
  • 8.27 Field Trip Health
    • 8.27.1 Field Trip Health Company Basic Information, and Sales Area
    • 8.27.2 Field Trip Health Business Segment/ Overview
    • 8.27.3 Field Trip Health Financials
      • 8.27.3.1 Investment in Research and Development
      • 8.27.3.2 Field Trip Health Sales Revenue (2018-2022)
      • 8.27.3.3 Field Trip Health Market Share (2018-2022)
    • 8.27.4 Field Trip Health Recent Developments
    • 8.27.5 Field Trip Health Business Strategy
    • 8.27.6 Field Trip Health Management Change
    • 8.27.7 Field Trip Health SWOT Analysis
      • 8.27.7.1 Strength
      • 8.27.7.2 Weakness
      • 8.27.7.3 Opportunity
      • 8.27.7.4 Threats
    • 8.27.8 Field Trip Health COVID-19 Impact Analysis
  • 8.28 Atai Life Sciences
    • 8.28.1 Atai Life Sciences Company Basic Information, and Sales Area
    • 8.28.2 Atai Life Sciences Business Segment/ Overview
    • 8.28.3 Atai Life Sciences Financials
      • 8.28.3.1 Investment in Research and Development
      • 8.28.3.2 Atai Life Sciences Sales Revenue (2018-2022)
      • 8.28.3.3 Atai Life Sciences Market Share (2018-2022)
    • 8.28.4 Atai Life Sciences Recent Developments
    • 8.28.5 Atai Life Sciences Business Strategy
    • 8.28.6 Atai Life Sciences Management Change
    • 8.28.7 Atai Life Sciences SWOT Analysis
      • 8.28.7.1 Strength
      • 8.28.7.2 Weakness
      • 8.28.7.3 Opportunity
      • 8.28.7.4 Threats
    • 8.28.8 Atai Life Sciences COVID-19 Impact Analysis
  • 8.29 Gh Research
    • 8.29.1 Gh Research Company Basic Information, and Sales Area
    • 8.29.2 Gh Research Business Segment/ Overview
    • 8.29.3 Gh Research Financials
      • 8.29.3.1 Investment in Research and Development
      • 8.29.3.2 Gh Research Sales Revenue (2018-2022)
      • 8.29.3.3 Gh Research Market Share (2018-2022)
    • 8.29.4 Gh Research Recent Developments
    • 8.29.5 Gh Research Business Strategy
    • 8.29.6 Gh Research Management Change
    • 8.29.7 Gh Research SWOT Analysis
      • 8.29.7.1 Strength
      • 8.29.7.2 Weakness
      • 8.29.7.3 Opportunity
      • 8.29.7.4 Threats
    • 8.29.8 Gh Research COVID-19 Impact Analysis
  • 8.30 Seelos Therapeutics
    • 8.30.1 Seelos Therapeutics Company Basic Information, and Sales Area
    • 8.30.2 Seelos Therapeutics Business Segment/ Overview
    • 8.30.3 Seelos Therapeutics Financials
      • 8.30.3.1 Investment in Research and Development
      • 8.30.3.2 Seelos Therapeutics Sales Revenue (2018-2022)
      • 8.30.3.3 Seelos Therapeutics Market Share (2018-2022)
    • 8.30.4 Seelos Therapeutics Recent Developments
    • 8.30.5 Seelos Therapeutics Business Strategy
    • 8.30.6 Seelos Therapeutics Management Change
    • 8.30.7 Seelos Therapeutics SWOT Analysis
      • 8.30.7.1 Strength
      • 8.30.7.2 Weakness
      • 8.30.7.3 Opportunity
      • 8.30.7.4 Threats
    • 8.30.8 Seelos Therapeutics COVID-19 Impact Analysis
  • 8.31 Small Pharma
    • 8.31.1 Small Pharma Company Basic Information, and Sales Area
    • 8.31.2 Small Pharma Business Segment/ Overview
    • 8.31.3 Small Pharma Financials
      • 8.31.3.1 Investment in Research and Development
      • 8.31.3.2 Small Pharma Sales Revenue (2018-2022)
      • 8.31.3.3 Small Pharma Market Share (2018-2022)
    • 8.31.4 Small Pharma Recent Developments
    • 8.31.5 Small Pharma Business Strategy
    • 8.31.6 Small Pharma Management Change
    • 8.31.7 Small Pharma SWOT Analysis
      • 8.31.7.1 Strength
      • 8.31.7.2 Weakness
      • 8.31.7.3 Opportunity
      • 8.31.7.4 Threats
    • 8.31.8 Small Pharma COVID-19 Impact Analysis
  • 8.32 Bright Minds Biosciences Incannex Health
    • 8.32.1 Bright Minds Biosciences Incannex Health Company Basic Information, and Sales Area
    • 8.32.2 Bright Minds Biosciences Incannex Health Business Segment/ Overview
    • 8.32.3 Bright Minds Biosciences Incannex Health Financials
      • 8.32.3.1 Investment in Research and Development
      • 8.32.3.2 Bright Minds Biosciences Incannex Health Sales Revenue (2018-2022)
      • 8.32.3.3 Bright Minds Biosciences Incannex Health Market Share (2018-2022)
    • 8.32.4 Bright Minds Biosciences Incannex Health Recent Developments
    • 8.32.5 Bright Minds Biosciences Incannex Health Business Strategy
    • 8.32.6 Bright Minds Biosciences Incannex Health Management Change
    • 8.32.7 Bright Minds Biosciences Incannex Health SWOT Analysis
      • 8.32.7.1 Strength
      • 8.32.7.2 Weakness
      • 8.32.7.3 Opportunity
      • 8.32.7.4 Threats
    • 8.32.8 Bright Minds Biosciences Incannex Health COVID-19 Impact Analysis
  • 8.33 Psybio Therapeutics
    • 8.33.1 Psybio Therapeutics Company Basic Information, and Sales Area
    • 8.33.2 Psybio Therapeutics Business Segment/ Overview
    • 8.33.3 Psybio Therapeutics Financials
      • 8.33.3.1 Investment in Research and Development
      • 8.33.3.2 Psybio Therapeutics Sales Revenue (2018-2022)
      • 8.33.3.3 Psybio Therapeutics Market Share (2018-2022)
    • 8.33.4 Psybio Therapeutics Recent Developments
    • 8.33.5 Psybio Therapeutics Business Strategy
    • 8.33.6 Psybio Therapeutics Management Change
    • 8.33.7 Psybio Therapeutics SWOT Analysis
      • 8.33.7.1 Strength
      • 8.33.7.2 Weakness
      • 8.33.7.3 Opportunity
      • 8.33.7.4 Threats
    • 8.33.8 Psybio Therapeutics COVID-19 Impact Analysis
  • 8.34 Universal Ibogaine
    • 8.34.1 Universal Ibogaine Company Basic Information, and Sales Area
    • 8.34.2 Universal Ibogaine Business Segment/ Overview
    • 8.34.3 Universal Ibogaine Financials
      • 8.34.3.1 Investment in Research and Development
      • 8.34.3.2 Universal Ibogaine Sales Revenue (2018-2022)
      • 8.34.3.3 Universal Ibogaine Market Share (2018-2022)
    • 8.34.4 Universal Ibogaine Recent Developments
    • 8.34.5 Universal Ibogaine Business Strategy
    • 8.34.6 Universal Ibogaine Management Change
    • 8.34.7 Universal Ibogaine SWOT Analysis
      • 8.34.7.1 Strength
      • 8.34.7.2 Weakness
      • 8.34.7.3 Opportunity
      • 8.34.7.4 Threats
    • 8.34.8 Universal Ibogaine COVID-19 Impact Analysis
  • 8.35 Levitee Labs
    • 8.35.1 Levitee Labs Company Basic Information, and Sales Area
    • 8.35.2 Levitee Labs Business Segment/ Overview
    • 8.35.3 Levitee Labs Financials
      • 8.35.3.1 Investment in Research and Development
      • 8.35.3.2 Levitee Labs Sales Revenue (2018-2022)
      • 8.35.3.3 Levitee Labs Market Share (2018-2022)
    • 8.35.4 Levitee Labs Recent Developments
    • 8.35.5 Levitee Labs Business Strategy
    • 8.35.6 Levitee Labs Management Change
    • 8.35.7 Levitee Labs SWOT Analysis
      • 8.35.7.1 Strength
      • 8.35.7.2 Weakness
      • 8.35.7.3 Opportunity
      • 8.35.7.4 Threats
    • 8.35.8 Levitee Labs COVID-19 Impact Analysis
  • 8.36 Mind Cure Health
    • 8.36.1 Mind Cure Health Company Basic Information, and Sales Area
    • 8.36.2 Mind Cure Health Business Segment/ Overview
    • 8.36.3 Mind Cure Health Financials
      • 8.36.3.1 Investment in Research and Development
      • 8.36.3.2 Mind Cure Health Sales Revenue (2018-2022)
      • 8.36.3.3 Mind Cure Health Market Share (2018-2022)
    • 8.36.4 Mind Cure Health Recent Developments
    • 8.36.5 Mind Cure Health Business Strategy
    • 8.36.6 Mind Cure Health Management Change
    • 8.36.7 Mind Cure Health SWOT Analysis
      • 8.36.7.1 Strength
      • 8.36.7.2 Weakness
      • 8.36.7.3 Opportunity
      • 8.36.7.4 Threats
    • 8.36.8 Mind Cure Health COVID-19 Impact Analysis
  • 8.37 Novamind
    • 8.37.1 Novamind Company Basic Information, and Sales Area
    • 8.37.2 Novamind Business Segment/ Overview
    • 8.37.3 Novamind Financials
      • 8.37.3.1 Investment in Research and Development
      • 8.37.3.2 Novamind Sales Revenue (2018-2022)
      • 8.37.3.3 Novamind Market Share (2018-2022)
    • 8.37.4 Novamind Recent Developments
    • 8.37.5 Novamind Business Strategy
    • 8.37.6 Novamind Management Change
    • 8.37.7 Novamind SWOT Analysis
      • 8.37.7.1 Strength
      • 8.37.7.2 Weakness
      • 8.37.7.3 Opportunity
      • 8.37.7.4 Threats
    • 8.37.8 Novamind COVID-19 Impact Analysis
  • 8.38 Clearmind Medicine
    • 8.38.1 Clearmind Medicine Company Basic Information, and Sales Area
    • 8.38.2 Clearmind Medicine Business Segment/ Overview
    • 8.38.3 Clearmind Medicine Financials
      • 8.38.3.1 Investment in Research and Development
      • 8.38.3.2 Clearmind Medicine Sales Revenue (2018-2022)
      • 8.38.3.3 Clearmind Medicine Market Share (2018-2022)
    • 8.38.4 Clearmind Medicine Recent Developments
    • 8.38.5 Clearmind Medicine Business Strategy
    • 8.38.6 Clearmind Medicine Management Change
    • 8.38.7 Clearmind Medicine SWOT Analysis
      • 8.38.7.1 Strength
      • 8.38.7.2 Weakness
      • 8.38.7.3 Opportunity
      • 8.38.7.4 Threats
    • 8.38.8 Clearmind Medicine COVID-19 Impact Analysis
  • 8.39 Mynd Life Science
    • 8.39.1 Mynd Life Science Company Basic Information, and Sales Area
    • 8.39.2 Mynd Life Science Business Segment/ Overview
    • 8.39.3 Mynd Life Science Financials
      • 8.39.3.1 Investment in Research and Development
      • 8.39.3.2 Mynd Life Science Sales Revenue (2018-2022)
      • 8.39.3.3 Mynd Life Science Market Share (2018-2022)
    • 8.39.4 Mynd Life Science Recent Developments
    • 8.39.5 Mynd Life Science Business Strategy
    • 8.39.6 Mynd Life Science Management Change
    • 8.39.7 Mynd Life Science SWOT Analysis
      • 8.39.7.1 Strength
      • 8.39.7.2 Weakness
      • 8.39.7.3 Opportunity
      • 8.39.7.4 Threats
    • 8.39.8 Mynd Life Science COVID-19 Impact Analysis
  • 8.40 Wesana Health
    • 8.40.1 Wesana Health Company Basic Information, and Sales Area
    • 8.40.2 Wesana Health Business Segment/ Overview
    • 8.40.3 Wesana Health Financials
      • 8.40.3.1 Investment in Research and Development
      • 8.40.3.2 Wesana Health Sales Revenue (2018-2022)
      • 8.40.3.3 Wesana Health Market Share (2018-2022)
    • 8.40.4 Wesana Health Recent Developments
    • 8.40.5 Wesana Health Business Strategy
    • 8.40.6 Wesana Health Management Change
    • 8.40.7 Wesana Health SWOT Analysis
      • 8.40.7.1 Strength
      • 8.40.7.2 Weakness
      • 8.40.7.3 Opportunity
      • 8.40.7.4 Threats
    • 8.40.8 Wesana Health COVID-19 Impact Analysis
  • 8.41 Psyched Wellness
    • 8.41.1 Psyched Wellness Company Basic Information, and Sales Area
    • 8.41.2 Psyched Wellness Business Segment/ Overview
    • 8.41.3 Psyched Wellness Financials
      • 8.41.3.1 Investment in Research and Development
      • 8.41.3.2 Psyched Wellness Sales Revenue (2018-2022)
      • 8.41.3.3 Psyched Wellness Market Share (2018-2022)
    • 8.41.4 Psyched Wellness Recent Developments
    • 8.41.5 Psyched Wellness Business Strategy
    • 8.41.6 Psyched Wellness Management Change
    • 8.41.7 Psyched Wellness SWOT Analysis
      • 8.41.7.1 Strength
      • 8.41.7.2 Weakness
      • 8.41.7.3 Opportunity
      • 8.41.7.4 Threats
    • 8.41.8 Psyched Wellness COVID-19 Impact Analysis
  • 8.42 Havn Life Sciences
    • 8.42.1 Havn Life Sciences Company Basic Information, and Sales Area
    • 8.42.2 Havn Life Sciences Business Segment/ Overview
    • 8.42.3 Havn Life Sciences Financials
      • 8.42.3.1 Investment in Research and Development
      • 8.42.3.2 Havn Life Sciences Sales Revenue (2018-2022)
      • 8.42.3.3 Havn Life Sciences Market Share (2018-2022)
    • 8.42.4 Havn Life Sciences Recent Developments
    • 8.42.5 Havn Life Sciences Business Strategy
    • 8.42.6 Havn Life Sciences Management Change
    • 8.42.7 Havn Life Sciences SWOT Analysis
      • 8.42.7.1 Strength
      • 8.42.7.2 Weakness
      • 8.42.7.3 Opportunity
      • 8.42.7.4 Threats
    • 8.42.8 Havn Life Sciences COVID-19 Impact Analysis
  • 8.43 Tryp Therapeutics
    • 8.43.1 Tryp Therapeutics Company Basic Information, and Sales Area
    • 8.43.2 Tryp Therapeutics Business Segment/ Overview
    • 8.43.3 Tryp Therapeutics Financials
      • 8.43.3.1 Investment in Research and Development
      • 8.43.3.2 Tryp Therapeutics Sales Revenue (2018-2022)
      • 8.43.3.3 Tryp Therapeutics Market Share (2018-2022)
    • 8.43.4 Tryp Therapeutics Recent Developments
    • 8.43.5 Tryp Therapeutics Business Strategy
    • 8.43.6 Tryp Therapeutics Management Change
    • 8.43.7 Tryp Therapeutics SWOT Analysis
      • 8.43.7.1 Strength
      • 8.43.7.2 Weakness
      • 8.43.7.3 Opportunity
      • 8.43.7.4 Threats
    • 8.43.8 Tryp Therapeutics COVID-19 Impact Analysis
  • 8.44 Psyence Group
    • 8.44.1 Psyence Group Company Basic Information, and Sales Area
    • 8.44.2 Psyence Group Business Segment/ Overview
    • 8.44.3 Psyence Group Financials
      • 8.44.3.1 Investment in Research and Development
      • 8.44.3.2 Psyence Group Sales Revenue (2018-2022)
      • 8.44.3.3 Psyence Group Market Share (2018-2022)
    • 8.44.4 Psyence Group Recent Developments
    • 8.44.5 Psyence Group Business Strategy
    • 8.44.6 Psyence Group Management Change
    • 8.44.7 Psyence Group SWOT Analysis
      • 8.44.7.1 Strength
      • 8.44.7.2 Weakness
      • 8.44.7.3 Opportunity
      • 8.44.7.4 Threats
    • 8.44.8 Psyence Group COVID-19 Impact Analysis
  • 8.45 Silo Pharma
    • 8.45.1 Silo Pharma Company Basic Information, and Sales Area
    • 8.45.2 Silo Pharma Business Segment/ Overview
    • 8.45.3 Silo Pharma Financials
      • 8.45.3.1 Investment in Research and Development
      • 8.45.3.2 Silo Pharma Sales Revenue (2018-2022)
      • 8.45.3.3 Silo Pharma Market Share (2018-2022)
    • 8.45.4 Silo Pharma Recent Developments
    • 8.45.5 Silo Pharma Business Strategy
    • 8.45.6 Silo Pharma Management Change
    • 8.45.7 Silo Pharma SWOT Analysis
      • 8.45.7.1 Strength
      • 8.45.7.2 Weakness
      • 8.45.7.3 Opportunity
      • 8.45.7.4 Threats
    • 8.45.8 Silo Pharma COVID-19 Impact Analysis
  • 8.46 Core One Labs
    • 8.46.1 Core One Labs Company Basic Information, and Sales Area
    • 8.46.2 Core One Labs Business Segment/ Overview
    • 8.46.3 Core One Labs Financials
      • 8.46.3.1 Investment in Research and Development
      • 8.46.3.2 Core One Labs Sales Revenue (2018-2022)
      • 8.46.3.3 Core One Labs Market Share (2018-2022)
    • 8.46.4 Core One Labs Recent Developments
    • 8.46.5 Core One Labs Business Strategy
    • 8.46.6 Core One Labs Management Change
    • 8.46.7 Core One Labs SWOT Analysis
      • 8.46.7.1 Strength
      • 8.46.7.2 Weakness
      • 8.46.7.3 Opportunity
      • 8.46.7.4 Threats
    • 8.46.8 Core One Labs COVID-19 Impact Analysis
  • 8.47 M2Bio Sciences
    • 8.47.1 M2Bio Sciences Company Basic Information, and Sales Area
    • 8.47.2 M2Bio Sciences Business Segment/ Overview
    • 8.47.3 M2Bio Sciences Financials
      • 8.47.3.1 Investment in Research and Development
      • 8.47.3.2 M2Bio Sciences Sales Revenue (2018-2022)
      • 8.47.3.3 M2Bio Sciences Market Share (2018-2022)
    • 8.47.4 M2Bio Sciences Recent Developments
    • 8.47.5 M2Bio Sciences Business Strategy
    • 8.47.6 M2Bio Sciences Management Change
    • 8.47.7 M2Bio Sciences SWOT Analysis
      • 8.47.7.1 Strength
      • 8.47.7.2 Weakness
      • 8.47.7.3 Opportunity
      • 8.47.7.4 Threats
    • 8.47.8 M2Bio Sciences COVID-19 Impact Analysis
  • 8.48 Neonmind Biosciences
    • 8.48.1 Neonmind Biosciences Company Basic Information, and Sales Area
    • 8.48.2 Neonmind Biosciences Business Segment/ Overview
    • 8.48.3 Neonmind Biosciences Financials
      • 8.48.3.1 Investment in Research and Development
      • 8.48.3.2 Neonmind Biosciences Sales Revenue (2018-2022)
      • 8.48.3.3 Neonmind Biosciences Market Share (2018-2022)
    • 8.48.4 Neonmind Biosciences Recent Developments
    • 8.48.5 Neonmind Biosciences Business Strategy
    • 8.48.6 Neonmind Biosciences Management Change
    • 8.48.7 Neonmind Biosciences SWOT Analysis
      • 8.48.7.1 Strength
      • 8.48.7.2 Weakness
      • 8.48.7.3 Opportunity
      • 8.48.7.4 Threats
    • 8.48.8 Neonmind Biosciences COVID-19 Impact Analysis
  • 8.49 Delic Corp
    • 8.49.1 Delic Corp Company Basic Information, and Sales Area
    • 8.49.2 Delic Corp Business Segment/ Overview
    • 8.49.3 Delic Corp Financials
      • 8.49.3.1 Investment in Research and Development
      • 8.49.3.2 Delic Corp Sales Revenue (2018-2022)
      • 8.49.3.3 Delic Corp Market Share (2018-2022)
    • 8.49.4 Delic Corp Recent Developments
    • 8.49.5 Delic Corp Business Strategy
    • 8.49.6 Delic Corp Management Change
    • 8.49.7 Delic Corp SWOT Analysis
      • 8.49.7.1 Strength
      • 8.49.7.2 Weakness
      • 8.49.7.3 Opportunity
      • 8.49.7.4 Threats
    • 8.49.8 Delic Corp COVID-19 Impact Analysis
  • 8.50 Nova Mentis Life Science
    • 8.50.1 Nova Mentis Life Science Company Basic Information, and Sales Area
    • 8.50.2 Nova Mentis Life Science Business Segment/ Overview
    • 8.50.3 Nova Mentis Life Science Financials
      • 8.50.3.1 Investment in Research and Development
      • 8.50.3.2 Nova Mentis Life Science Sales Revenue (2018-2022)
      • 8.50.3.3 Nova Mentis Life Science Market Share (2018-2022)
    • 8.50.4 Nova Mentis Life Science Recent Developments
    • 8.50.5 Nova Mentis Life Science Business Strategy
    • 8.50.6 Nova Mentis Life Science Management Change
    • 8.50.7 Nova Mentis Life Science SWOT Analysis
      • 8.50.7.1 Strength
      • 8.50.7.2 Weakness
      • 8.50.7.3 Opportunity
      • 8.50.7.4 Threats
    • 8.50.8 Nova Mentis Life Science COVID-19 Impact Analysis
  • 8.51 Beckley Psytech
    • 8.51.1 Beckley Psytech Company Basic Information, and Sales Area
    • 8.51.2 Beckley Psytech Business Segment/ Overview
    • 8.51.3 Beckley Psytech Financials
      • 8.51.3.1 Investment in Research and Development
      • 8.51.3.2 Beckley Psytech Sales Revenue (2018-2022)
      • 8.51.3.3 Beckley Psytech Market Share (2018-2022)
    • 8.51.4 Beckley Psytech Recent Developments
    • 8.51.5 Beckley Psytech Business Strategy
    • 8.51.6 Beckley Psytech Management Change
    • 8.51.7 Beckley Psytech SWOT Analysis
      • 8.51.7.1 Strength
      • 8.51.7.2 Weakness
      • 8.51.7.3 Opportunity
      • 8.51.7.4 Threats
    • 8.51.8 Beckley Psytech COVID-19 Impact Analysis
  • 8.52 Delix Therapeutics
    • 8.52.1 Delix Therapeutics Company Basic Information, and Sales Area
    • 8.52.2 Delix Therapeutics Business Segment/ Overview
    • 8.52.3 Delix Therapeutics Financials
      • 8.52.3.1 Investment in Research and Development
      • 8.52.3.2 Delix Therapeutics Sales Revenue (2018-2022)
      • 8.52.3.3 Delix Therapeutics Market Share (2018-2022)
    • 8.52.4 Delix Therapeutics Recent Developments
    • 8.52.5 Delix Therapeutics Business Strategy
    • 8.52.6 Delix Therapeutics Management Change
    • 8.52.7 Delix Therapeutics SWOT Analysis
      • 8.52.7.1 Strength
      • 8.52.7.2 Weakness
      • 8.52.7.3 Opportunity
      • 8.52.7.4 Threats
    • 8.52.8 Delix Therapeutics COVID-19 Impact Analysis
  • 8.53 Diamond Therapeutics
    • 8.53.1 Diamond Therapeutics Company Basic Information, and Sales Area
    • 8.53.2 Diamond Therapeutics Business Segment/ Overview
    • 8.53.3 Diamond Therapeutics Financials
      • 8.53.3.1 Investment in Research and Development
      • 8.53.3.2 Diamond Therapeutics Sales Revenue (2018-2022)
      • 8.53.3.3 Diamond Therapeutics Market Share (2018-2022)
    • 8.53.4 Diamond Therapeutics Recent Developments
    • 8.53.5 Diamond Therapeutics Business Strategy
    • 8.53.6 Diamond Therapeutics Management Change
    • 8.53.7 Diamond Therapeutics SWOT Analysis
      • 8.53.7.1 Strength
      • 8.53.7.2 Weakness
      • 8.53.7.3 Opportunity
      • 8.53.7.4 Threats
    • 8.53.8 Diamond Therapeutics COVID-19 Impact Analysis
  • 8.54 Tactogen
    • 8.54.1 Tactogen Company Basic Information, and Sales Area
    • 8.54.2 Tactogen Business Segment/ Overview
    • 8.54.3 Tactogen Financials
      • 8.54.3.1 Investment in Research and Development
      • 8.54.3.2 Tactogen Sales Revenue (2018-2022)
      • 8.54.3.3 Tactogen Market Share (2018-2022)
    • 8.54.4 Tactogen Recent Developments
    • 8.54.5 Tactogen Business Strategy
    • 8.54.6 Tactogen Management Change
    • 8.54.7 Tactogen SWOT Analysis
      • 8.54.7.1 Strength
      • 8.54.7.2 Weakness
      • 8.54.7.3 Opportunity
      • 8.54.7.4 Threats
    • 8.54.8 Tactogen COVID-19 Impact Analysis
  • 8.55 Psygen Labs Inc
    • 8.55.1 Psygen Labs Inc Company Basic Information, and Sales Area
    • 8.55.2 Psygen Labs Inc Business Segment/ Overview
    • 8.55.3 Psygen Labs Inc Financials
      • 8.55.3.1 Investment in Research and Development
      • 8.55.3.2 Psygen Labs Inc Sales Revenue (2018-2022)
      • 8.55.3.3 Psygen Labs Inc Market Share (2018-2022)
    • 8.55.4 Psygen Labs Inc Recent Developments
    • 8.55.5 Psygen Labs Inc Business Strategy
    • 8.55.6 Psygen Labs Inc Management Change
    • 8.55.7 Psygen Labs Inc SWOT Analysis
      • 8.55.7.1 Strength
      • 8.55.7.2 Weakness
      • 8.55.7.3 Opportunity
      • 8.55.7.4 Threats
    • 8.55.8 Psygen Labs Inc COVID-19 Impact Analysis
  • 8.56 Bexson Biomedical
    • 8.56.1 Bexson Biomedical Company Basic Information, and Sales Area
    • 8.56.2 Bexson Biomedical Business Segment/ Overview
    • 8.56.3 Bexson Biomedical Financials
      • 8.56.3.1 Investment in Research and Development
      • 8.56.3.2 Bexson Biomedical Sales Revenue (2018-2022)
      • 8.56.3.3 Bexson Biomedical Market Share (2018-2022)
    • 8.56.4 Bexson Biomedical Recent Developments
    • 8.56.5 Bexson Biomedical Business Strategy
    • 8.56.6 Bexson Biomedical Management Change
    • 8.56.7 Bexson Biomedical SWOT Analysis
      • 8.56.7.1 Strength
      • 8.56.7.2 Weakness
      • 8.56.7.3 Opportunity
      • 8.56.7.4 Threats
    • 8.56.8 Bexson Biomedical COVID-19 Impact Analysis
  • 8.57 Eleusis Biotech
    • 8.57.1 Eleusis Biotech Company Basic Information, and Sales Area
    • 8.57.2 Eleusis Biotech Business Segment/ Overview
    • 8.57.3 Eleusis Biotech Financials
      • 8.57.3.1 Investment in Research and Development
      • 8.57.3.2 Eleusis Biotech Sales Revenue (2018-2022)
      • 8.57.3.3 Eleusis Biotech Market Share (2018-2022)
    • 8.57.4 Eleusis Biotech Recent Developments
    • 8.57.5 Eleusis Biotech Business Strategy
    • 8.57.6 Eleusis Biotech Management Change
    • 8.57.7 Eleusis Biotech SWOT Analysis
      • 8.57.7.1 Strength
      • 8.57.7.2 Weakness
      • 8.57.7.3 Opportunity
      • 8.57.7.4 Threats
    • 8.57.8 Eleusis Biotech COVID-19 Impact Analysis
  • 8.58 Psilera Biosceince
    • 8.58.1 Psilera Biosceince Company Basic Information, and Sales Area
    • 8.58.2 Psilera Biosceince Business Segment/ Overview
    • 8.58.3 Psilera Biosceince Financials
      • 8.58.3.1 Investment in Research and Development
      • 8.58.3.2 Psilera Biosceince Sales Revenue (2018-2022)
      • 8.58.3.3 Psilera Biosceince Market Share (2018-2022)
    • 8.58.4 Psilera Biosceince Recent Developments
    • 8.58.5 Psilera Biosceince Business Strategy
    • 8.58.6 Psilera Biosceince Management Change
    • 8.58.7 Psilera Biosceince SWOT Analysis
      • 8.58.7.1 Strength
      • 8.58.7.2 Weakness
      • 8.58.7.3 Opportunity
      • 8.58.7.4 Threats
    • 8.58.8 Psilera Biosceince COVID-19 Impact Analysis
  • 8.59 Octarine Bio
    • 8.59.1 Octarine Bio Company Basic Information, and Sales Area
    • 8.59.2 Octarine Bio Business Segment/ Overview
    • 8.59.3 Octarine Bio Financials
      • 8.59.3.1 Investment in Research and Development
      • 8.59.3.2 Octarine Bio Sales Revenue (2018-2022)
      • 8.59.3.3 Octarine Bio Market Share (2018-2022)
    • 8.59.4 Octarine Bio Recent Developments
    • 8.59.5 Octarine Bio Business Strategy
    • 8.59.6 Octarine Bio Management Change
    • 8.59.7 Octarine Bio SWOT Analysis
      • 8.59.7.1 Strength
      • 8.59.7.2 Weakness
      • 8.59.7.3 Opportunity
      • 8.59.7.4 Threats
    • 8.59.8 Octarine Bio COVID-19 Impact Analysis
  • 8.60 Heading Health
    • 8.60.1 Heading Health Company Basic Information, and Sales Area
    • 8.60.2 Heading Health Business Segment/ Overview
    • 8.60.3 Heading Health Financials
      • 8.60.3.1 Investment in Research and Development
      • 8.60.3.2 Heading Health Sales Revenue (2018-2022)
      • 8.60.3.3 Heading Health Market Share (2018-2022)
    • 8.60.4 Heading Health Recent Developments
    • 8.60.5 Heading Health Business Strategy
    • 8.60.6 Heading Health Management Change
    • 8.60.7 Heading Health SWOT Analysis
      • 8.60.7.1 Strength
      • 8.60.7.2 Weakness
      • 8.60.7.3 Opportunity
      • 8.60.7.4 Threats
    • 8.60.8 Heading Health COVID-19 Impact Analysis
  • 8.61 Maps Public Benefit Corporation (Pbc)
    • 8.61.1 Maps Public Benefit Corporation (Pbc) Company Basic Information, and Sales Area
    • 8.61.2 Maps Public Benefit Corporation (Pbc) Business Segment/ Overview
    • 8.61.3 Maps Public Benefit Corporation (Pbc) Financials
      • 8.61.3.1 Investment in Research and Development
      • 8.61.3.2 Maps Public Benefit Corporation (Pbc) Sales Revenue (2018-2022)
      • 8.61.3.3 Maps Public Benefit Corporation (Pbc) Market Share (2018-2022)
    • 8.61.4 Maps Public Benefit Corporation (Pbc) Recent Developments
    • 8.61.5 Maps Public Benefit Corporation (Pbc) Business Strategy
    • 8.61.6 Maps Public Benefit Corporation (Pbc) Management Change
    • 8.61.7 Maps Public Benefit Corporation (Pbc) SWOT Analysis
      • 8.61.7.1 Strength
      • 8.61.7.2 Weakness
      • 8.61.7.3 Opportunity
      • 8.61.7.4 Threats
    • 8.61.8 Maps Public Benefit Corporation (Pbc) COVID-19 Impact Analysis
  • 8.62 Aphrodite Health
    • 8.62.1 Aphrodite Health Company Basic Information, and Sales Area
    • 8.62.2 Aphrodite Health Business Segment/ Overview
    • 8.62.3 Aphrodite Health Financials
      • 8.62.3.1 Investment in Research and Development
      • 8.62.3.2 Aphrodite Health Sales Revenue (2018-2022)
      • 8.62.3.3 Aphrodite Health Market Share (2018-2022)
    • 8.62.4 Aphrodite Health Recent Developments
    • 8.62.5 Aphrodite Health Business Strategy
    • 8.62.6 Aphrodite Health Management Change
    • 8.62.7 Aphrodite Health SWOT Analysis
      • 8.62.7.1 Strength
      • 8.62.7.2 Weakness
      • 8.62.7.3 Opportunity
      • 8.62.7.4 Threats
    • 8.62.8 Aphrodite Health COVID-19 Impact Analysis
  • 8.63 Terran Biosciences
    • 8.63.1 Terran Biosciences Company Basic Information, and Sales Area
    • 8.63.2 Terran Biosciences Business Segment/ Overview
    • 8.63.3 Terran Biosciences Financials
      • 8.63.3.1 Investment in Research and Development
      • 8.63.3.2 Terran Biosciences Sales Revenue (2018-2022)
      • 8.63.3.3 Terran Biosciences Market Share (2018-2022)
    • 8.63.4 Terran Biosciences Recent Developments
    • 8.63.5 Terran Biosciences Business Strategy
    • 8.63.6 Terran Biosciences Management Change
    • 8.63.7 Terran Biosciences SWOT Analysis
      • 8.63.7.1 Strength
      • 8.63.7.2 Weakness
      • 8.63.7.3 Opportunity
      • 8.63.7.4 Threats
    • 8.63.8 Terran Biosciences COVID-19 Impact Analysis
  • 8.64 Mycrodose Therapeutics
    • 8.64.1 Mycrodose Therapeutics Company Basic Information, and Sales Area
    • 8.64.2 Mycrodose Therapeutics Business Segment/ Overview
    • 8.64.3 Mycrodose Therapeutics Financials
      • 8.64.3.1 Investment in Research and Development
      • 8.64.3.2 Mycrodose Therapeutics Sales Revenue (2018-2022)
      • 8.64.3.3 Mycrodose Therapeutics Market Share (2018-2022)
    • 8.64.4 Mycrodose Therapeutics Recent Developments
    • 8.64.5 Mycrodose Therapeutics Business Strategy
    • 8.64.6 Mycrodose Therapeutics Management Change
    • 8.64.7 Mycrodose Therapeutics SWOT Analysis
      • 8.64.7.1 Strength
      • 8.64.7.2 Weakness
      • 8.64.7.3 Opportunity
      • 8.64.7.4 Threats
    • 8.64.8 Mycrodose Therapeutics COVID-19 Impact Analysis
  • 8.65 Reset Pharma
    • 8.65.1 Reset Pharma Company Basic Information, and Sales Area
    • 8.65.2 Reset Pharma Business Segment/ Overview
    • 8.65.3 Reset Pharma Financials
      • 8.65.3.1 Investment in Research and Development
      • 8.65.3.2 Reset Pharma Sales Revenue (2018-2022)
      • 8.65.3.3 Reset Pharma Market Share (2018-2022)
    • 8.65.4 Reset Pharma Recent Developments
    • 8.65.5 Reset Pharma Business Strategy
    • 8.65.6 Reset Pharma Management Change
    • 8.65.7 Reset Pharma SWOT Analysis
      • 8.65.7.1 Strength
      • 8.65.7.2 Weakness
      • 8.65.7.3 Opportunity
      • 8.65.7.4 Threats
    • 8.65.8 Reset Pharma COVID-19 Impact Analysis
  • 8.66 Clerkenwell Health
    • 8.66.1 Clerkenwell Health Company Basic Information, and Sales Area
    • 8.66.2 Clerkenwell Health Business Segment/ Overview
    • 8.66.3 Clerkenwell Health Financials
      • 8.66.3.1 Investment in Research and Development
      • 8.66.3.2 Clerkenwell Health Sales Revenue (2018-2022)
      • 8.66.3.3 Clerkenwell Health Market Share (2018-2022)
    • 8.66.4 Clerkenwell Health Recent Developments
    • 8.66.5 Clerkenwell Health Business Strategy
    • 8.66.6 Clerkenwell Health Management Change
    • 8.66.7 Clerkenwell Health SWOT Analysis
      • 8.66.7.1 Strength
      • 8.66.7.2 Weakness
      • 8.66.7.3 Opportunity
      • 8.66.7.4 Threats
    • 8.66.8 Clerkenwell Health COVID-19 Impact Analysis
  • 8.67 Alvarius Pharmaceuticals
    • 8.67.1 Alvarius Pharmaceuticals Company Basic Information, and Sales Area
    • 8.67.2 Alvarius Pharmaceuticals Business Segment/ Overview
    • 8.67.3 Alvarius Pharmaceuticals Financials
      • 8.67.3.1 Investment in Research and Development
      • 8.67.3.2 Alvarius Pharmaceuticals Sales Revenue (2018-2022)
      • 8.67.3.3 Alvarius Pharmaceuticals Market Share (2018-2022)
    • 8.67.4 Alvarius Pharmaceuticals Recent Developments
    • 8.67.5 Alvarius Pharmaceuticals Business Strategy
    • 8.67.6 Alvarius Pharmaceuticals Management Change
    • 8.67.7 Alvarius Pharmaceuticals SWOT Analysis
      • 8.67.7.1 Strength
      • 8.67.7.2 Weakness
      • 8.67.7.3 Opportunity
      • 8.67.7.4 Threats
    • 8.67.8 Alvarius Pharmaceuticals COVID-19 Impact Analysis
  • 8.68 Ceruvia Lifesciences
    • 8.68.1 Ceruvia Lifesciences Company Basic Information, and Sales Area
    • 8.68.2 Ceruvia Lifesciences Business Segment/ Overview
    • 8.68.3 Ceruvia Lifesciences Financials
      • 8.68.3.1 Investment in Research and Development
      • 8.68.3.2 Ceruvia Lifesciences Sales Revenue (2018-2022)
      • 8.68.3.3 Ceruvia Lifesciences Market Share (2018-2022)
    • 8.68.4 Ceruvia Lifesciences Recent Developments
    • 8.68.5 Ceruvia Lifesciences Business Strategy
    • 8.68.6 Ceruvia Lifesciences Management Change
    • 8.68.7 Ceruvia Lifesciences SWOT Analysis
      • 8.68.7.1 Strength
      • 8.68.7.2 Weakness
      • 8.68.7.3 Opportunity
      • 8.68.7.4 Threats
    • 8.68.8 Ceruvia Lifesciences COVID-19 Impact Analysis

This chapter covers in-detailed insights regarding type segments to understand consumer interests and provide a revenue stream for each type. Type segment analysis help in making a better business decision to maximize profitability by focusing resources on those market type that are relatively favorable to their goals.

Chapter 9 Global Psychedelic Therapeutics Market by Type Segmentation Analysis (2018-2030)
  • 9.1 Detailed Qualitative Analysis
  • 9.2 Global Psychedelic Therapeutics Revenue and Share (%) by Type (2018-2030)
    • 9.2.1 GHB Market Size
      • 9.2.1.1 Global GHB Market Share and Revenue (USD Million) for 2018-2030
      • 9.2.1.2 Psychedelic Therapeutics Market for GHB, by Country (2021 Vs 2024)
    • 9.2.2 Ketamine Market Size
      • 9.2.2.1 Global Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 9.2.2.2 Psychedelic Therapeutics Market for Ketamine, by Country (2021 Vs 2024)
    • 9.2.3 MDMA Market Size
      • 9.2.3.1 Global MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 9.2.3.2 Psychedelic Therapeutics Market for MDMA, by Country (2021 Vs 2024)
    • 9.2.4 Psilocybin Market Size
      • 9.2.4.1 Global Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 9.2.4.2 Psychedelic Therapeutics Market for Psilocybin, by Country (2021 Vs 2024)
    • 9.2.5 DMT Market Size
      • 9.2.5.1 Global DMT Market Share and Revenue (USD Million) for 2018-2030
      • 9.2.5.2 Psychedelic Therapeutics Market for DMT, by Country (2021 Vs 2024)
    • 9.2.6 Ayahuasca Market Size
      • 9.2.6.1 Global Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 9.2.6.2 Psychedelic Therapeutics Market for Ayahuasca, by Country (2021 Vs 2024)
    • 9.2.7 LSD Market Size
      • 9.2.7.1 Global LSD Market Share and Revenue (USD Million) for 2018-2030
      • 9.2.7.2 Psychedelic Therapeutics Market for LSD, by Country (2021 Vs 2024)
    • 9.2.8 Other Market Size
      • 9.2.8.1 Global Other Market Share and Revenue (USD Million) for 2018-2030
      • 9.2.8.2 Psychedelic Therapeutics Market for Other, by Country (2021 Vs 2024)

This chapter covers in-detailed insights regarding type segments to understand consumer interests and provide a revenue stream for each type. Type segment analysis help in making a better business decision to maximize profitability by focusing resources on those market type that are relatively favorable to their goals.

Chapter 10 Global Psychedelic Therapeutics Market by Origin of Psychedelic Substance Segmentation Analysis (2018-2030)
  • 10.1 Detailed Qualitative Analysis
  • 10.2 Global Psychedelic Therapeutics Revenue and Share (%) by Origin of Psychedelic Substance (2018-2030)
    • 10.2.1 Synthetic Substances Market Size
      • 10.2.1.1 Global Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 10.2.1.2 Psychedelic Therapeutics Market for Synthetic Substances, by Country (2021 Vs 2024)
    • 10.2.2 Natural Substances Market Size
      • 10.2.2.1 Global Natural Substances Market Share and Revenue (USD Million) for 2018-2030
      • 10.2.2.2 Psychedelic Therapeutics Market for Natural Substances, by Country (2021 Vs 2024)

This chapter covers in-detailed insights regarding type segments to understand consumer interests and provide a revenue stream for each type. Type segment analysis help in making a better business decision to maximize profitability by focusing resources on those market type that are relatively favorable to their goals.

Chapter 11 Global Psychedelic Therapeutics Market by Target Therapeutic Area Segmentation Analysis (2018-2030)
  • 11.1 Detailed Qualitative Analysis
  • 11.2 Global Psychedelic Therapeutics Revenue and Share (%) by Target Therapeutic Area (2018-2030)
    • 11.2.1 Depression and Anxiety Disorders Market Size
      • 11.2.1.1 Global Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 11.2.1.2 Psychedelic Therapeutics Market for Depression and Anxiety Disorders, by Country (2021 Vs 2024)
    • 11.2.2 Pain Disorders Market Size
      • 11.2.2.1 Global Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 11.2.2.2 Psychedelic Therapeutics Market for Pain Disorders, by Country (2021 Vs 2024)
    • 11.2.3 Sleep-Related Disorders Market Size
      • 11.2.3.1 Global Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 11.2.3.2 Psychedelic Therapeutics Market for Sleep-Related Disorders, by Country (2021 Vs 2024)
    • 11.2.4 Trauma Market Size
      • 11.2.4.1 Global Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 11.2.4.2 Psychedelic Therapeutics Market for Trauma, by Country (2021 Vs 2024)
    • 11.2.5 Other Market Size
      • 11.2.5.1 Global Other Market Share and Revenue (USD Million) for 2018-2030
      • 11.2.5.2 Psychedelic Therapeutics Market for Other, by Country (2021 Vs 2024)

This chapter categorizes detailed perceptions into an application segment based on end users’ needs, and preferences to understand their requirements and purchasing patterns effectively. It analyzes the current trends of the market that mainly consists of information related to new product use, trends in consumer demand, and available close substitutes of the product.

Chapter 12 Global Psychedelic Therapeutics Market Regional Analysis
  • 12.1 Detailed Qualitative Analysis
  • 12.2 Global Psychedelic Therapeutics Market Revenue by Region (2018-2030)
  • 12.3 Global Psychedelic Therapeutics Market Share (%) by Region (2018-2030)
Chapter 13 North America Psychedelic Therapeutics Market Outlook (2018 - 2030)
  • 13.1 North America
    • 13.1.1 North America Psychedelic Therapeutics Market Trends and Analysis
    • 13.1.2 North America Psychedelic Therapeutics Market by Country, 2018-2030
    • 13.1.3 North America Psychedelic Therapeutics Market Attractiveness Analysis by Country
  • 13.2 North America Psychedelic Therapeutics Market Size (2018-2030)
    • 13.2.1 North America Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 13.2.1.1 GHB
        • 13.2.1.1.1 North America GHB Market Share and Revenue (USD Million) for 2018-2030
      • 13.2.1.2 Ketamine
        • 13.2.1.2.1 North America Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 13.2.1.3 MDMA
        • 13.2.1.3.1 North America MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 13.2.1.4 Psilocybin
        • 13.2.1.4.1 North America Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 13.2.1.5 DMT
        • 13.2.1.5.1 North America DMT Market Share and Revenue (USD Million) for 2018-2030
      • 13.2.1.6 Ayahuasca
        • 13.2.1.6.1 North America Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 13.2.1.7 LSD
        • 13.2.1.7.1 North America LSD Market Share and Revenue (USD Million) for 2018-2030
      • 13.2.1.8 Other
        • 13.2.1.8.1 North America Other Market Share and Revenue (USD Million) for 2018-2030
    • 13.2.2 North America Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 13.2.2.1 Synthetic Substances
        • 13.2.2.1.1 North America Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 13.2.2.2 Natural Substances
        • 13.2.2.2.1 North America Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 13.2.3 North America Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 13.2.3.1 Depression and Anxiety Disorders
        • 13.2.3.1.1 North America Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 13.2.3.2 Pain Disorders
        • 13.2.3.2.1 North America Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 13.2.3.3 Sleep-Related Disorders
        • 13.2.3.3.1 North America Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 13.2.3.4 Trauma
        • 13.2.3.4.1 North America Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 13.2.3.5 Other
        • 13.2.3.5.1 North America Other Market Share and Revenue (USD Million) for 2018-2030
  • 13.3 United States Psychedelic Therapeutics Market Size (2018-2030)
    • 13.3.1 United States Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 13.3.1.1 GHB
        • 13.3.1.1.1 United States GHB Market Share and Revenue (USD Million) for 2018-2030
      • 13.3.1.2 Ketamine
        • 13.3.1.2.1 United States Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 13.3.1.3 MDMA
        • 13.3.1.3.1 United States MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 13.3.1.4 Psilocybin
        • 13.3.1.4.1 United States Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 13.3.1.5 DMT
        • 13.3.1.5.1 United States DMT Market Share and Revenue (USD Million) for 2018-2030
      • 13.3.1.6 Ayahuasca
        • 13.3.1.6.1 United States Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 13.3.1.7 LSD
        • 13.3.1.7.1 United States LSD Market Share and Revenue (USD Million) for 2018-2030
      • 13.3.1.8 Other
        • 13.3.1.8.1 United States Other Market Share and Revenue (USD Million) for 2018-2030
    • 13.3.2 United States Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 13.3.2.1 Synthetic Substances
        • 13.3.2.1.1 United States Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 13.3.2.2 Natural Substances
        • 13.3.2.2.1 United States Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 13.3.3 United States Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 13.3.3.1 Depression and Anxiety Disorders
        • 13.3.3.1.1 United States Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 13.3.3.2 Pain Disorders
        • 13.3.3.2.1 United States Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 13.3.3.3 Sleep-Related Disorders
        • 13.3.3.3.1 United States Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 13.3.3.4 Trauma
        • 13.3.3.4.1 United States Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 13.3.3.5 Other
        • 13.3.3.5.1 United States Other Market Share and Revenue (USD Million) for 2018-2030
  • 13.4 Canada Psychedelic Therapeutics Market Size (2018-2030)
    • 13.4.1 Canada Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 13.4.1.1 GHB
        • 13.4.1.1.1 Canada GHB Market Share and Revenue (USD Million) for 2018-2030
      • 13.4.1.2 Ketamine
        • 13.4.1.2.1 Canada Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 13.4.1.3 MDMA
        • 13.4.1.3.1 Canada MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 13.4.1.4 Psilocybin
        • 13.4.1.4.1 Canada Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 13.4.1.5 DMT
        • 13.4.1.5.1 Canada DMT Market Share and Revenue (USD Million) for 2018-2030
      • 13.4.1.6 Ayahuasca
        • 13.4.1.6.1 Canada Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 13.4.1.7 LSD
        • 13.4.1.7.1 Canada LSD Market Share and Revenue (USD Million) for 2018-2030
      • 13.4.1.8 Other
        • 13.4.1.8.1 Canada Other Market Share and Revenue (USD Million) for 2018-2030
    • 13.4.2 Canada Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 13.4.2.1 Synthetic Substances
        • 13.4.2.1.1 Canada Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 13.4.2.2 Natural Substances
        • 13.4.2.2.1 Canada Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 13.4.3 Canada Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 13.4.3.1 Depression and Anxiety Disorders
        • 13.4.3.1.1 Canada Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 13.4.3.2 Pain Disorders
        • 13.4.3.2.1 Canada Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 13.4.3.3 Sleep-Related Disorders
        • 13.4.3.3.1 Canada Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 13.4.3.4 Trauma
        • 13.4.3.4.1 Canada Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 13.4.3.5 Other
        • 13.4.3.5.1 Canada Other Market Share and Revenue (USD Million) for 2018-2030
  • 13.5 Mexico Psychedelic Therapeutics Market Size (2018-2030)
    • 13.5.1 Mexico Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 13.5.1.1 GHB
        • 13.5.1.1.1 Mexico GHB Market Share and Revenue (USD Million) for 2018-2030
      • 13.5.1.2 Ketamine
        • 13.5.1.2.1 Mexico Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 13.5.1.3 MDMA
        • 13.5.1.3.1 Mexico MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 13.5.1.4 Psilocybin
        • 13.5.1.4.1 Mexico Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 13.5.1.5 DMT
        • 13.5.1.5.1 Mexico DMT Market Share and Revenue (USD Million) for 2018-2030
      • 13.5.1.6 Ayahuasca
        • 13.5.1.6.1 Mexico Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 13.5.1.7 LSD
        • 13.5.1.7.1 Mexico LSD Market Share and Revenue (USD Million) for 2018-2030
      • 13.5.1.8 Other
        • 13.5.1.8.1 Mexico Other Market Share and Revenue (USD Million) for 2018-2030
    • 13.5.2 Mexico Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 13.5.2.1 Synthetic Substances
        • 13.5.2.1.1 Mexico Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 13.5.2.2 Natural Substances
        • 13.5.2.2.1 Mexico Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 13.5.3 Mexico Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 13.5.3.1 Depression and Anxiety Disorders
        • 13.5.3.1.1 Mexico Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 13.5.3.2 Pain Disorders
        • 13.5.3.2.1 Mexico Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 13.5.3.3 Sleep-Related Disorders
        • 13.5.3.3.1 Mexico Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 13.5.3.4 Trauma
        • 13.5.3.4.1 Mexico Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 13.5.3.5 Other
        • 13.5.3.5.1 Mexico Other Market Share and Revenue (USD Million) for 2018-2030
Chapter 14 Europe Psychedelic Therapeutics Market Outlook (2018 - 2030)
  • 14.1 Europe
    • 14.1.1 Europe Psychedelic Therapeutics Market Trends and Analysis
    • 14.1.2 Europe Psychedelic Therapeutics Market by Country, 2018-2030
    • 14.1.3 Europe Psychedelic Therapeutics Market Attractiveness Analysis by Country
  • 14.2 Europe Psychedelic Therapeutics Market Size (2018-2030)
    • 14.2.1 Europe Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 14.2.1.1 GHB
        • 14.2.1.1.1 Europe GHB Market Share and Revenue (USD Million) for 2018-2030
      • 14.2.1.2 Ketamine
        • 14.2.1.2.1 Europe Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 14.2.1.3 MDMA
        • 14.2.1.3.1 Europe MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 14.2.1.4 Psilocybin
        • 14.2.1.4.1 Europe Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 14.2.1.5 DMT
        • 14.2.1.5.1 Europe DMT Market Share and Revenue (USD Million) for 2018-2030
      • 14.2.1.6 Ayahuasca
        • 14.2.1.6.1 Europe Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 14.2.1.7 LSD
        • 14.2.1.7.1 Europe LSD Market Share and Revenue (USD Million) for 2018-2030
      • 14.2.1.8 Other
        • 14.2.1.8.1 Europe Other Market Share and Revenue (USD Million) for 2018-2030
    • 14.2.2 Europe Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 14.2.2.1 Synthetic Substances
        • 14.2.2.1.1 Europe Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 14.2.2.2 Natural Substances
        • 14.2.2.2.1 Europe Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 14.2.3 Europe Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 14.2.3.1 Depression and Anxiety Disorders
        • 14.2.3.1.1 Europe Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.2.3.2 Pain Disorders
        • 14.2.3.2.1 Europe Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.2.3.3 Sleep-Related Disorders
        • 14.2.3.3.1 Europe Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.2.3.4 Trauma
        • 14.2.3.4.1 Europe Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 14.2.3.5 Other
        • 14.2.3.5.1 Europe Other Market Share and Revenue (USD Million) for 2018-2030
  • 14.3 United Kingdom Psychedelic Therapeutics Market Size (2018-2030)
    • 14.3.1 United Kingdom Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 14.3.1.1 GHB
        • 14.3.1.1.1 United Kingdom GHB Market Share and Revenue (USD Million) for 2018-2030
      • 14.3.1.2 Ketamine
        • 14.3.1.2.1 United Kingdom Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 14.3.1.3 MDMA
        • 14.3.1.3.1 United Kingdom MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 14.3.1.4 Psilocybin
        • 14.3.1.4.1 United Kingdom Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 14.3.1.5 DMT
        • 14.3.1.5.1 United Kingdom DMT Market Share and Revenue (USD Million) for 2018-2030
      • 14.3.1.6 Ayahuasca
        • 14.3.1.6.1 United Kingdom Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 14.3.1.7 LSD
        • 14.3.1.7.1 United Kingdom LSD Market Share and Revenue (USD Million) for 2018-2030
      • 14.3.1.8 Other
        • 14.3.1.8.1 United Kingdom Other Market Share and Revenue (USD Million) for 2018-2030
    • 14.3.2 United Kingdom Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 14.3.2.1 Synthetic Substances
        • 14.3.2.1.1 United Kingdom Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 14.3.2.2 Natural Substances
        • 14.3.2.2.1 United Kingdom Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 14.3.3 United Kingdom Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 14.3.3.1 Depression and Anxiety Disorders
        • 14.3.3.1.1 United Kingdom Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.3.3.2 Pain Disorders
        • 14.3.3.2.1 United Kingdom Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.3.3.3 Sleep-Related Disorders
        • 14.3.3.3.1 United Kingdom Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.3.3.4 Trauma
        • 14.3.3.4.1 United Kingdom Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 14.3.3.5 Other
        • 14.3.3.5.1 United Kingdom Other Market Share and Revenue (USD Million) for 2018-2030
  • 14.4 France Psychedelic Therapeutics Market Size (2018-2030)
    • 14.4.1 France Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 14.4.1.1 GHB
        • 14.4.1.1.1 France GHB Market Share and Revenue (USD Million) for 2018-2030
      • 14.4.1.2 Ketamine
        • 14.4.1.2.1 France Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 14.4.1.3 MDMA
        • 14.4.1.3.1 France MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 14.4.1.4 Psilocybin
        • 14.4.1.4.1 France Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 14.4.1.5 DMT
        • 14.4.1.5.1 France DMT Market Share and Revenue (USD Million) for 2018-2030
      • 14.4.1.6 Ayahuasca
        • 14.4.1.6.1 France Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 14.4.1.7 LSD
        • 14.4.1.7.1 France LSD Market Share and Revenue (USD Million) for 2018-2030
      • 14.4.1.8 Other
        • 14.4.1.8.1 France Other Market Share and Revenue (USD Million) for 2018-2030
    • 14.4.2 France Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 14.4.2.1 Synthetic Substances
        • 14.4.2.1.1 France Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 14.4.2.2 Natural Substances
        • 14.4.2.2.1 France Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 14.4.3 France Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 14.4.3.1 Depression and Anxiety Disorders
        • 14.4.3.1.1 France Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.4.3.2 Pain Disorders
        • 14.4.3.2.1 France Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.4.3.3 Sleep-Related Disorders
        • 14.4.3.3.1 France Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.4.3.4 Trauma
        • 14.4.3.4.1 France Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 14.4.3.5 Other
        • 14.4.3.5.1 France Other Market Share and Revenue (USD Million) for 2018-2030
  • 14.5 Germany Psychedelic Therapeutics Market Size (2018-2030)
    • 14.5.1 Germany Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 14.5.1.1 GHB
        • 14.5.1.1.1 Germany GHB Market Share and Revenue (USD Million) for 2018-2030
      • 14.5.1.2 Ketamine
        • 14.5.1.2.1 Germany Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 14.5.1.3 MDMA
        • 14.5.1.3.1 Germany MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 14.5.1.4 Psilocybin
        • 14.5.1.4.1 Germany Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 14.5.1.5 DMT
        • 14.5.1.5.1 Germany DMT Market Share and Revenue (USD Million) for 2018-2030
      • 14.5.1.6 Ayahuasca
        • 14.5.1.6.1 Germany Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 14.5.1.7 LSD
        • 14.5.1.7.1 Germany LSD Market Share and Revenue (USD Million) for 2018-2030
      • 14.5.1.8 Other
        • 14.5.1.8.1 Germany Other Market Share and Revenue (USD Million) for 2018-2030
    • 14.5.2 Germany Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 14.5.2.1 Synthetic Substances
        • 14.5.2.1.1 Germany Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 14.5.2.2 Natural Substances
        • 14.5.2.2.1 Germany Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 14.5.3 Germany Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 14.5.3.1 Depression and Anxiety Disorders
        • 14.5.3.1.1 Germany Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.5.3.2 Pain Disorders
        • 14.5.3.2.1 Germany Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.5.3.3 Sleep-Related Disorders
        • 14.5.3.3.1 Germany Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.5.3.4 Trauma
        • 14.5.3.4.1 Germany Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 14.5.3.5 Other
        • 14.5.3.5.1 Germany Other Market Share and Revenue (USD Million) for 2018-2030
  • 14.6 Italy Psychedelic Therapeutics Market Size (2018-2030)
    • 14.6.1 Italy Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 14.6.1.1 GHB
        • 14.6.1.1.1 Italy GHB Market Share and Revenue (USD Million) for 2018-2030
      • 14.6.1.2 Ketamine
        • 14.6.1.2.1 Italy Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 14.6.1.3 MDMA
        • 14.6.1.3.1 Italy MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 14.6.1.4 Psilocybin
        • 14.6.1.4.1 Italy Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 14.6.1.5 DMT
        • 14.6.1.5.1 Italy DMT Market Share and Revenue (USD Million) for 2018-2030
      • 14.6.1.6 Ayahuasca
        • 14.6.1.6.1 Italy Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 14.6.1.7 LSD
        • 14.6.1.7.1 Italy LSD Market Share and Revenue (USD Million) for 2018-2030
      • 14.6.1.8 Other
        • 14.6.1.8.1 Italy Other Market Share and Revenue (USD Million) for 2018-2030
    • 14.6.2 Italy Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 14.6.2.1 Synthetic Substances
        • 14.6.2.1.1 Italy Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 14.6.2.2 Natural Substances
        • 14.6.2.2.1 Italy Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 14.6.3 Italy Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 14.6.3.1 Depression and Anxiety Disorders
        • 14.6.3.1.1 Italy Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.6.3.2 Pain Disorders
        • 14.6.3.2.1 Italy Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.6.3.3 Sleep-Related Disorders
        • 14.6.3.3.1 Italy Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.6.3.4 Trauma
        • 14.6.3.4.1 Italy Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 14.6.3.5 Other
        • 14.6.3.5.1 Italy Other Market Share and Revenue (USD Million) for 2018-2030
  • 14.7 Russia Psychedelic Therapeutics Market Size (2018-2030)
    • 14.7.1 Russia Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 14.7.1.1 GHB
        • 14.7.1.1.1 Russia GHB Market Share and Revenue (USD Million) for 2018-2030
      • 14.7.1.2 Ketamine
        • 14.7.1.2.1 Russia Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 14.7.1.3 MDMA
        • 14.7.1.3.1 Russia MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 14.7.1.4 Psilocybin
        • 14.7.1.4.1 Russia Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 14.7.1.5 DMT
        • 14.7.1.5.1 Russia DMT Market Share and Revenue (USD Million) for 2018-2030
      • 14.7.1.6 Ayahuasca
        • 14.7.1.6.1 Russia Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 14.7.1.7 LSD
        • 14.7.1.7.1 Russia LSD Market Share and Revenue (USD Million) for 2018-2030
      • 14.7.1.8 Other
        • 14.7.1.8.1 Russia Other Market Share and Revenue (USD Million) for 2018-2030
    • 14.7.2 Russia Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 14.7.2.1 Synthetic Substances
        • 14.7.2.1.1 Russia Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 14.7.2.2 Natural Substances
        • 14.7.2.2.1 Russia Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 14.7.3 Russia Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 14.7.3.1 Depression and Anxiety Disorders
        • 14.7.3.1.1 Russia Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.7.3.2 Pain Disorders
        • 14.7.3.2.1 Russia Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.7.3.3 Sleep-Related Disorders
        • 14.7.3.3.1 Russia Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.7.3.4 Trauma
        • 14.7.3.4.1 Russia Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 14.7.3.5 Other
        • 14.7.3.5.1 Russia Other Market Share and Revenue (USD Million) for 2018-2030
  • 14.8 Spain Psychedelic Therapeutics Market Size (2018-2030)
    • 14.8.1 Spain Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 14.8.1.1 GHB
        • 14.8.1.1.1 Spain GHB Market Share and Revenue (USD Million) for 2018-2030
      • 14.8.1.2 Ketamine
        • 14.8.1.2.1 Spain Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 14.8.1.3 MDMA
        • 14.8.1.3.1 Spain MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 14.8.1.4 Psilocybin
        • 14.8.1.4.1 Spain Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 14.8.1.5 DMT
        • 14.8.1.5.1 Spain DMT Market Share and Revenue (USD Million) for 2018-2030
      • 14.8.1.6 Ayahuasca
        • 14.8.1.6.1 Spain Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 14.8.1.7 LSD
        • 14.8.1.7.1 Spain LSD Market Share and Revenue (USD Million) for 2018-2030
      • 14.8.1.8 Other
        • 14.8.1.8.1 Spain Other Market Share and Revenue (USD Million) for 2018-2030
    • 14.8.2 Spain Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 14.8.2.1 Synthetic Substances
        • 14.8.2.1.1 Spain Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 14.8.2.2 Natural Substances
        • 14.8.2.2.1 Spain Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 14.8.3 Spain Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 14.8.3.1 Depression and Anxiety Disorders
        • 14.8.3.1.1 Spain Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.8.3.2 Pain Disorders
        • 14.8.3.2.1 Spain Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.8.3.3 Sleep-Related Disorders
        • 14.8.3.3.1 Spain Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.8.3.4 Trauma
        • 14.8.3.4.1 Spain Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 14.8.3.5 Other
        • 14.8.3.5.1 Spain Other Market Share and Revenue (USD Million) for 2018-2030
  • 14.9 Sweden Psychedelic Therapeutics Market Size (2018-2030)
    • 14.9.1 Sweden Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 14.9.1.1 GHB
        • 14.9.1.1.1 Sweden GHB Market Share and Revenue (USD Million) for 2018-2030
      • 14.9.1.2 Ketamine
        • 14.9.1.2.1 Sweden Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 14.9.1.3 MDMA
        • 14.9.1.3.1 Sweden MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 14.9.1.4 Psilocybin
        • 14.9.1.4.1 Sweden Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 14.9.1.5 DMT
        • 14.9.1.5.1 Sweden DMT Market Share and Revenue (USD Million) for 2018-2030
      • 14.9.1.6 Ayahuasca
        • 14.9.1.6.1 Sweden Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 14.9.1.7 LSD
        • 14.9.1.7.1 Sweden LSD Market Share and Revenue (USD Million) for 2018-2030
      • 14.9.1.8 Other
        • 14.9.1.8.1 Sweden Other Market Share and Revenue (USD Million) for 2018-2030
    • 14.9.2 Sweden Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 14.9.2.1 Synthetic Substances
        • 14.9.2.1.1 Sweden Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 14.9.2.2 Natural Substances
        • 14.9.2.2.1 Sweden Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 14.9.3 Sweden Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 14.9.3.1 Depression and Anxiety Disorders
        • 14.9.3.1.1 Sweden Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.9.3.2 Pain Disorders
        • 14.9.3.2.1 Sweden Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.9.3.3 Sleep-Related Disorders
        • 14.9.3.3.1 Sweden Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.9.3.4 Trauma
        • 14.9.3.4.1 Sweden Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 14.9.3.5 Other
        • 14.9.3.5.1 Sweden Other Market Share and Revenue (USD Million) for 2018-2030
  • 14.10 Denmark Psychedelic Therapeutics Market Size (2018-2030)
    • 14.10.1 Denmark Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 14.10.1.1 GHB
        • 14.10.1.1.1 Denmark GHB Market Share and Revenue (USD Million) for 2018-2030
      • 14.10.1.2 Ketamine
        • 14.10.1.2.1 Denmark Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 14.10.1.3 MDMA
        • 14.10.1.3.1 Denmark MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 14.10.1.4 Psilocybin
        • 14.10.1.4.1 Denmark Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 14.10.1.5 DMT
        • 14.10.1.5.1 Denmark DMT Market Share and Revenue (USD Million) for 2018-2030
      • 14.10.1.6 Ayahuasca
        • 14.10.1.6.1 Denmark Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 14.10.1.7 LSD
        • 14.10.1.7.1 Denmark LSD Market Share and Revenue (USD Million) for 2018-2030
      • 14.10.1.8 Other
        • 14.10.1.8.1 Denmark Other Market Share and Revenue (USD Million) for 2018-2030
    • 14.10.2 Denmark Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 14.10.2.1 Synthetic Substances
        • 14.10.2.1.1 Denmark Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 14.10.2.2 Natural Substances
        • 14.10.2.2.1 Denmark Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 14.10.3 Denmark Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 14.10.3.1 Depression and Anxiety Disorders
        • 14.10.3.1.1 Denmark Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.10.3.2 Pain Disorders
        • 14.10.3.2.1 Denmark Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.10.3.3 Sleep-Related Disorders
        • 14.10.3.3.1 Denmark Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.10.3.4 Trauma
        • 14.10.3.4.1 Denmark Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 14.10.3.5 Other
        • 14.10.3.5.1 Denmark Other Market Share and Revenue (USD Million) for 2018-2030
  • 14.11 Netherlands Psychedelic Therapeutics Market Size (2018-2030)
    • 14.11.1 Netherlands Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 14.11.1.1 GHB
        • 14.11.1.1.1 Netherlands GHB Market Share and Revenue (USD Million) for 2018-2030
      • 14.11.1.2 Ketamine
        • 14.11.1.2.1 Netherlands Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 14.11.1.3 MDMA
        • 14.11.1.3.1 Netherlands MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 14.11.1.4 Psilocybin
        • 14.11.1.4.1 Netherlands Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 14.11.1.5 DMT
        • 14.11.1.5.1 Netherlands DMT Market Share and Revenue (USD Million) for 2018-2030
      • 14.11.1.6 Ayahuasca
        • 14.11.1.6.1 Netherlands Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 14.11.1.7 LSD
        • 14.11.1.7.1 Netherlands LSD Market Share and Revenue (USD Million) for 2018-2030
      • 14.11.1.8 Other
        • 14.11.1.8.1 Netherlands Other Market Share and Revenue (USD Million) for 2018-2030
    • 14.11.2 Netherlands Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 14.11.2.1 Synthetic Substances
        • 14.11.2.1.1 Netherlands Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 14.11.2.2 Natural Substances
        • 14.11.2.2.1 Netherlands Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 14.11.3 Netherlands Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 14.11.3.1 Depression and Anxiety Disorders
        • 14.11.3.1.1 Netherlands Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.11.3.2 Pain Disorders
        • 14.11.3.2.1 Netherlands Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.11.3.3 Sleep-Related Disorders
        • 14.11.3.3.1 Netherlands Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.11.3.4 Trauma
        • 14.11.3.4.1 Netherlands Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 14.11.3.5 Other
        • 14.11.3.5.1 Netherlands Other Market Share and Revenue (USD Million) for 2018-2030
  • 14.12 Switzerland Psychedelic Therapeutics Market Size (2018-2030)
    • 14.12.1 Switzerland Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 14.12.1.1 GHB
        • 14.12.1.1.1 Switzerland GHB Market Share and Revenue (USD Million) for 2018-2030
      • 14.12.1.2 Ketamine
        • 14.12.1.2.1 Switzerland Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 14.12.1.3 MDMA
        • 14.12.1.3.1 Switzerland MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 14.12.1.4 Psilocybin
        • 14.12.1.4.1 Switzerland Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 14.12.1.5 DMT
        • 14.12.1.5.1 Switzerland DMT Market Share and Revenue (USD Million) for 2018-2030
      • 14.12.1.6 Ayahuasca
        • 14.12.1.6.1 Switzerland Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 14.12.1.7 LSD
        • 14.12.1.7.1 Switzerland LSD Market Share and Revenue (USD Million) for 2018-2030
      • 14.12.1.8 Other
        • 14.12.1.8.1 Switzerland Other Market Share and Revenue (USD Million) for 2018-2030
    • 14.12.2 Switzerland Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 14.12.2.1 Synthetic Substances
        • 14.12.2.1.1 Switzerland Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 14.12.2.2 Natural Substances
        • 14.12.2.2.1 Switzerland Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 14.12.3 Switzerland Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 14.12.3.1 Depression and Anxiety Disorders
        • 14.12.3.1.1 Switzerland Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.12.3.2 Pain Disorders
        • 14.12.3.2.1 Switzerland Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.12.3.3 Sleep-Related Disorders
        • 14.12.3.3.1 Switzerland Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.12.3.4 Trauma
        • 14.12.3.4.1 Switzerland Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 14.12.3.5 Other
        • 14.12.3.5.1 Switzerland Other Market Share and Revenue (USD Million) for 2018-2030
  • 14.13 Belgium Psychedelic Therapeutics Market Size (2018-2030)
    • 14.13.1 Belgium Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 14.13.1.1 GHB
        • 14.13.1.1.1 Belgium GHB Market Share and Revenue (USD Million) for 2018-2030
      • 14.13.1.2 Ketamine
        • 14.13.1.2.1 Belgium Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 14.13.1.3 MDMA
        • 14.13.1.3.1 Belgium MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 14.13.1.4 Psilocybin
        • 14.13.1.4.1 Belgium Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 14.13.1.5 DMT
        • 14.13.1.5.1 Belgium DMT Market Share and Revenue (USD Million) for 2018-2030
      • 14.13.1.6 Ayahuasca
        • 14.13.1.6.1 Belgium Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 14.13.1.7 LSD
        • 14.13.1.7.1 Belgium LSD Market Share and Revenue (USD Million) for 2018-2030
      • 14.13.1.8 Other
        • 14.13.1.8.1 Belgium Other Market Share and Revenue (USD Million) for 2018-2030
    • 14.13.2 Belgium Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 14.13.2.1 Synthetic Substances
        • 14.13.2.1.1 Belgium Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 14.13.2.2 Natural Substances
        • 14.13.2.2.1 Belgium Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 14.13.3 Belgium Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 14.13.3.1 Depression and Anxiety Disorders
        • 14.13.3.1.1 Belgium Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.13.3.2 Pain Disorders
        • 14.13.3.2.1 Belgium Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.13.3.3 Sleep-Related Disorders
        • 14.13.3.3.1 Belgium Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 14.13.3.4 Trauma
        • 14.13.3.4.1 Belgium Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 14.13.3.5 Other
        • 14.13.3.5.1 Belgium Other Market Share and Revenue (USD Million) for 2018-2030
Chapter 15 Asia Pacific Psychedelic Therapeutics Market Outlook (2018 - 2030)
  • 15.1 Asia Pacific
    • 15.1.1 Asia Pacific Psychedelic Therapeutics Market Trends and Analysis
    • 15.1.2 Asia Pacific Psychedelic Therapeutics Market by Country, 2018-2030
    • 15.1.3 Asia Pacific Psychedelic Therapeutics Market Attractiveness Analysis by Country
  • 15.2 Asia Pacific Psychedelic Therapeutics Market Size (2018-2030)
    • 15.2.1 Asia Pacific Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 15.2.1.1 GHB
        • 15.2.1.1.1 Asia Pacific GHB Market Share and Revenue (USD Million) for 2018-2030
      • 15.2.1.2 Ketamine
        • 15.2.1.2.1 Asia Pacific Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 15.2.1.3 MDMA
        • 15.2.1.3.1 Asia Pacific MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 15.2.1.4 Psilocybin
        • 15.2.1.4.1 Asia Pacific Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 15.2.1.5 DMT
        • 15.2.1.5.1 Asia Pacific DMT Market Share and Revenue (USD Million) for 2018-2030
      • 15.2.1.6 Ayahuasca
        • 15.2.1.6.1 Asia Pacific Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 15.2.1.7 LSD
        • 15.2.1.7.1 Asia Pacific LSD Market Share and Revenue (USD Million) for 2018-2030
      • 15.2.1.8 Other
        • 15.2.1.8.1 Asia Pacific Other Market Share and Revenue (USD Million) for 2018-2030
    • 15.2.2 Asia Pacific Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 15.2.2.1 Synthetic Substances
        • 15.2.2.1.1 Asia Pacific Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 15.2.2.2 Natural Substances
        • 15.2.2.2.1 Asia Pacific Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 15.2.3 Asia Pacific Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 15.2.3.1 Depression and Anxiety Disorders
        • 15.2.3.1.1 Asia Pacific Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.2.3.2 Pain Disorders
        • 15.2.3.2.1 Asia Pacific Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.2.3.3 Sleep-Related Disorders
        • 15.2.3.3.1 Asia Pacific Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.2.3.4 Trauma
        • 15.2.3.4.1 Asia Pacific Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 15.2.3.5 Other
        • 15.2.3.5.1 Asia Pacific Other Market Share and Revenue (USD Million) for 2018-2030
  • 15.3 China Psychedelic Therapeutics Market Size (2018-2030)
    • 15.3.1 China Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 15.3.1.1 GHB
        • 15.3.1.1.1 China GHB Market Share and Revenue (USD Million) for 2018-2030
      • 15.3.1.2 Ketamine
        • 15.3.1.2.1 China Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 15.3.1.3 MDMA
        • 15.3.1.3.1 China MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 15.3.1.4 Psilocybin
        • 15.3.1.4.1 China Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 15.3.1.5 DMT
        • 15.3.1.5.1 China DMT Market Share and Revenue (USD Million) for 2018-2030
      • 15.3.1.6 Ayahuasca
        • 15.3.1.6.1 China Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 15.3.1.7 LSD
        • 15.3.1.7.1 China LSD Market Share and Revenue (USD Million) for 2018-2030
      • 15.3.1.8 Other
        • 15.3.1.8.1 China Other Market Share and Revenue (USD Million) for 2018-2030
    • 15.3.2 China Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 15.3.2.1 Synthetic Substances
        • 15.3.2.1.1 China Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 15.3.2.2 Natural Substances
        • 15.3.2.2.1 China Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 15.3.3 China Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 15.3.3.1 Depression and Anxiety Disorders
        • 15.3.3.1.1 China Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.3.3.2 Pain Disorders
        • 15.3.3.2.1 China Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.3.3.3 Sleep-Related Disorders
        • 15.3.3.3.1 China Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.3.3.4 Trauma
        • 15.3.3.4.1 China Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 15.3.3.5 Other
        • 15.3.3.5.1 China Other Market Share and Revenue (USD Million) for 2018-2030
  • 15.4 Japan Psychedelic Therapeutics Market Size (2018-2030)
    • 15.4.1 Japan Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 15.4.1.1 GHB
        • 15.4.1.1.1 Japan GHB Market Share and Revenue (USD Million) for 2018-2030
      • 15.4.1.2 Ketamine
        • 15.4.1.2.1 Japan Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 15.4.1.3 MDMA
        • 15.4.1.3.1 Japan MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 15.4.1.4 Psilocybin
        • 15.4.1.4.1 Japan Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 15.4.1.5 DMT
        • 15.4.1.5.1 Japan DMT Market Share and Revenue (USD Million) for 2018-2030
      • 15.4.1.6 Ayahuasca
        • 15.4.1.6.1 Japan Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 15.4.1.7 LSD
        • 15.4.1.7.1 Japan LSD Market Share and Revenue (USD Million) for 2018-2030
      • 15.4.1.8 Other
        • 15.4.1.8.1 Japan Other Market Share and Revenue (USD Million) for 2018-2030
    • 15.4.2 Japan Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 15.4.2.1 Synthetic Substances
        • 15.4.2.1.1 Japan Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 15.4.2.2 Natural Substances
        • 15.4.2.2.1 Japan Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 15.4.3 Japan Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 15.4.3.1 Depression and Anxiety Disorders
        • 15.4.3.1.1 Japan Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.4.3.2 Pain Disorders
        • 15.4.3.2.1 Japan Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.4.3.3 Sleep-Related Disorders
        • 15.4.3.3.1 Japan Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.4.3.4 Trauma
        • 15.4.3.4.1 Japan Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 15.4.3.5 Other
        • 15.4.3.5.1 Japan Other Market Share and Revenue (USD Million) for 2018-2030
  • 15.5 Korea Psychedelic Therapeutics Market Size (2018-2030)
    • 15.5.1 Korea Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 15.5.1.1 GHB
        • 15.5.1.1.1 Korea GHB Market Share and Revenue (USD Million) for 2018-2030
      • 15.5.1.2 Ketamine
        • 15.5.1.2.1 Korea Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 15.5.1.3 MDMA
        • 15.5.1.3.1 Korea MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 15.5.1.4 Psilocybin
        • 15.5.1.4.1 Korea Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 15.5.1.5 DMT
        • 15.5.1.5.1 Korea DMT Market Share and Revenue (USD Million) for 2018-2030
      • 15.5.1.6 Ayahuasca
        • 15.5.1.6.1 Korea Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 15.5.1.7 LSD
        • 15.5.1.7.1 Korea LSD Market Share and Revenue (USD Million) for 2018-2030
      • 15.5.1.8 Other
        • 15.5.1.8.1 Korea Other Market Share and Revenue (USD Million) for 2018-2030
    • 15.5.2 Korea Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 15.5.2.1 Synthetic Substances
        • 15.5.2.1.1 Korea Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 15.5.2.2 Natural Substances
        • 15.5.2.2.1 Korea Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 15.5.3 Korea Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 15.5.3.1 Depression and Anxiety Disorders
        • 15.5.3.1.1 Korea Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.5.3.2 Pain Disorders
        • 15.5.3.2.1 Korea Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.5.3.3 Sleep-Related Disorders
        • 15.5.3.3.1 Korea Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.5.3.4 Trauma
        • 15.5.3.4.1 Korea Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 15.5.3.5 Other
        • 15.5.3.5.1 Korea Other Market Share and Revenue (USD Million) for 2018-2030
  • 15.6 India Psychedelic Therapeutics Market Size (2018-2030)
    • 15.6.1 India Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 15.6.1.1 GHB
        • 15.6.1.1.1 India GHB Market Share and Revenue (USD Million) for 2018-2030
      • 15.6.1.2 Ketamine
        • 15.6.1.2.1 India Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 15.6.1.3 MDMA
        • 15.6.1.3.1 India MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 15.6.1.4 Psilocybin
        • 15.6.1.4.1 India Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 15.6.1.5 DMT
        • 15.6.1.5.1 India DMT Market Share and Revenue (USD Million) for 2018-2030
      • 15.6.1.6 Ayahuasca
        • 15.6.1.6.1 India Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 15.6.1.7 LSD
        • 15.6.1.7.1 India LSD Market Share and Revenue (USD Million) for 2018-2030
      • 15.6.1.8 Other
        • 15.6.1.8.1 India Other Market Share and Revenue (USD Million) for 2018-2030
    • 15.6.2 India Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 15.6.2.1 Synthetic Substances
        • 15.6.2.1.1 India Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 15.6.2.2 Natural Substances
        • 15.6.2.2.1 India Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 15.6.3 India Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 15.6.3.1 Depression and Anxiety Disorders
        • 15.6.3.1.1 India Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.6.3.2 Pain Disorders
        • 15.6.3.2.1 India Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.6.3.3 Sleep-Related Disorders
        • 15.6.3.3.1 India Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.6.3.4 Trauma
        • 15.6.3.4.1 India Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 15.6.3.5 Other
        • 15.6.3.5.1 India Other Market Share and Revenue (USD Million) for 2018-2030
  • 15.7 Australia Psychedelic Therapeutics Market Size (2018-2030)
    • 15.7.1 Australia Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 15.7.1.1 GHB
        • 15.7.1.1.1 Australia GHB Market Share and Revenue (USD Million) for 2018-2030
      • 15.7.1.2 Ketamine
        • 15.7.1.2.1 Australia Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 15.7.1.3 MDMA
        • 15.7.1.3.1 Australia MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 15.7.1.4 Psilocybin
        • 15.7.1.4.1 Australia Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 15.7.1.5 DMT
        • 15.7.1.5.1 Australia DMT Market Share and Revenue (USD Million) for 2018-2030
      • 15.7.1.6 Ayahuasca
        • 15.7.1.6.1 Australia Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 15.7.1.7 LSD
        • 15.7.1.7.1 Australia LSD Market Share and Revenue (USD Million) for 2018-2030
      • 15.7.1.8 Other
        • 15.7.1.8.1 Australia Other Market Share and Revenue (USD Million) for 2018-2030
    • 15.7.2 Australia Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 15.7.2.1 Synthetic Substances
        • 15.7.2.1.1 Australia Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 15.7.2.2 Natural Substances
        • 15.7.2.2.1 Australia Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 15.7.3 Australia Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 15.7.3.1 Depression and Anxiety Disorders
        • 15.7.3.1.1 Australia Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.7.3.2 Pain Disorders
        • 15.7.3.2.1 Australia Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.7.3.3 Sleep-Related Disorders
        • 15.7.3.3.1 Australia Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.7.3.4 Trauma
        • 15.7.3.4.1 Australia Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 15.7.3.5 Other
        • 15.7.3.5.1 Australia Other Market Share and Revenue (USD Million) for 2018-2030
  • 15.8 Philippines Psychedelic Therapeutics Market Size (2018-2030)
    • 15.8.1 Philippines Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 15.8.1.1 GHB
        • 15.8.1.1.1 Philippines GHB Market Share and Revenue (USD Million) for 2018-2030
      • 15.8.1.2 Ketamine
        • 15.8.1.2.1 Philippines Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 15.8.1.3 MDMA
        • 15.8.1.3.1 Philippines MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 15.8.1.4 Psilocybin
        • 15.8.1.4.1 Philippines Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 15.8.1.5 DMT
        • 15.8.1.5.1 Philippines DMT Market Share and Revenue (USD Million) for 2018-2030
      • 15.8.1.6 Ayahuasca
        • 15.8.1.6.1 Philippines Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 15.8.1.7 LSD
        • 15.8.1.7.1 Philippines LSD Market Share and Revenue (USD Million) for 2018-2030
      • 15.8.1.8 Other
        • 15.8.1.8.1 Philippines Other Market Share and Revenue (USD Million) for 2018-2030
    • 15.8.2 Philippines Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 15.8.2.1 Synthetic Substances
        • 15.8.2.1.1 Philippines Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 15.8.2.2 Natural Substances
        • 15.8.2.2.1 Philippines Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 15.8.3 Philippines Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 15.8.3.1 Depression and Anxiety Disorders
        • 15.8.3.1.1 Philippines Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.8.3.2 Pain Disorders
        • 15.8.3.2.1 Philippines Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.8.3.3 Sleep-Related Disorders
        • 15.8.3.3.1 Philippines Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.8.3.4 Trauma
        • 15.8.3.4.1 Philippines Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 15.8.3.5 Other
        • 15.8.3.5.1 Philippines Other Market Share and Revenue (USD Million) for 2018-2030
  • 15.9 Singapore Psychedelic Therapeutics Market Size (2018-2030)
    • 15.9.1 Singapore Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 15.9.1.1 GHB
        • 15.9.1.1.1 Singapore GHB Market Share and Revenue (USD Million) for 2018-2030
      • 15.9.1.2 Ketamine
        • 15.9.1.2.1 Singapore Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 15.9.1.3 MDMA
        • 15.9.1.3.1 Singapore MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 15.9.1.4 Psilocybin
        • 15.9.1.4.1 Singapore Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 15.9.1.5 DMT
        • 15.9.1.5.1 Singapore DMT Market Share and Revenue (USD Million) for 2018-2030
      • 15.9.1.6 Ayahuasca
        • 15.9.1.6.1 Singapore Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 15.9.1.7 LSD
        • 15.9.1.7.1 Singapore LSD Market Share and Revenue (USD Million) for 2018-2030
      • 15.9.1.8 Other
        • 15.9.1.8.1 Singapore Other Market Share and Revenue (USD Million) for 2018-2030
    • 15.9.2 Singapore Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 15.9.2.1 Synthetic Substances
        • 15.9.2.1.1 Singapore Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 15.9.2.2 Natural Substances
        • 15.9.2.2.1 Singapore Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 15.9.3 Singapore Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 15.9.3.1 Depression and Anxiety Disorders
        • 15.9.3.1.1 Singapore Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.9.3.2 Pain Disorders
        • 15.9.3.2.1 Singapore Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.9.3.3 Sleep-Related Disorders
        • 15.9.3.3.1 Singapore Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.9.3.4 Trauma
        • 15.9.3.4.1 Singapore Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 15.9.3.5 Other
        • 15.9.3.5.1 Singapore Other Market Share and Revenue (USD Million) for 2018-2030
  • 15.10 Malaysia Psychedelic Therapeutics Market Size (2018-2030)
    • 15.10.1 Malaysia Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 15.10.1.1 GHB
        • 15.10.1.1.1 Malaysia GHB Market Share and Revenue (USD Million) for 2018-2030
      • 15.10.1.2 Ketamine
        • 15.10.1.2.1 Malaysia Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 15.10.1.3 MDMA
        • 15.10.1.3.1 Malaysia MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 15.10.1.4 Psilocybin
        • 15.10.1.4.1 Malaysia Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 15.10.1.5 DMT
        • 15.10.1.5.1 Malaysia DMT Market Share and Revenue (USD Million) for 2018-2030
      • 15.10.1.6 Ayahuasca
        • 15.10.1.6.1 Malaysia Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 15.10.1.7 LSD
        • 15.10.1.7.1 Malaysia LSD Market Share and Revenue (USD Million) for 2018-2030
      • 15.10.1.8 Other
        • 15.10.1.8.1 Malaysia Other Market Share and Revenue (USD Million) for 2018-2030
    • 15.10.2 Malaysia Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 15.10.2.1 Synthetic Substances
        • 15.10.2.1.1 Malaysia Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 15.10.2.2 Natural Substances
        • 15.10.2.2.1 Malaysia Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 15.10.3 Malaysia Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 15.10.3.1 Depression and Anxiety Disorders
        • 15.10.3.1.1 Malaysia Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.10.3.2 Pain Disorders
        • 15.10.3.2.1 Malaysia Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.10.3.3 Sleep-Related Disorders
        • 15.10.3.3.1 Malaysia Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.10.3.4 Trauma
        • 15.10.3.4.1 Malaysia Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 15.10.3.5 Other
        • 15.10.3.5.1 Malaysia Other Market Share and Revenue (USD Million) for 2018-2030
  • 15.11 Thailand Psychedelic Therapeutics Market Size (2018-2030)
    • 15.11.1 Thailand Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 15.11.1.1 GHB
        • 15.11.1.1.1 Thailand GHB Market Share and Revenue (USD Million) for 2018-2030
      • 15.11.1.2 Ketamine
        • 15.11.1.2.1 Thailand Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 15.11.1.3 MDMA
        • 15.11.1.3.1 Thailand MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 15.11.1.4 Psilocybin
        • 15.11.1.4.1 Thailand Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 15.11.1.5 DMT
        • 15.11.1.5.1 Thailand DMT Market Share and Revenue (USD Million) for 2018-2030
      • 15.11.1.6 Ayahuasca
        • 15.11.1.6.1 Thailand Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 15.11.1.7 LSD
        • 15.11.1.7.1 Thailand LSD Market Share and Revenue (USD Million) for 2018-2030
      • 15.11.1.8 Other
        • 15.11.1.8.1 Thailand Other Market Share and Revenue (USD Million) for 2018-2030
    • 15.11.2 Thailand Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 15.11.2.1 Synthetic Substances
        • 15.11.2.1.1 Thailand Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 15.11.2.2 Natural Substances
        • 15.11.2.2.1 Thailand Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 15.11.3 Thailand Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 15.11.3.1 Depression and Anxiety Disorders
        • 15.11.3.1.1 Thailand Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.11.3.2 Pain Disorders
        • 15.11.3.2.1 Thailand Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.11.3.3 Sleep-Related Disorders
        • 15.11.3.3.1 Thailand Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.11.3.4 Trauma
        • 15.11.3.4.1 Thailand Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 15.11.3.5 Other
        • 15.11.3.5.1 Thailand Other Market Share and Revenue (USD Million) for 2018-2030
  • 15.12 Indonesia Psychedelic Therapeutics Market Size (2018-2030)
    • 15.12.1 Indonesia Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 15.12.1.1 GHB
        • 15.12.1.1.1 Indonesia GHB Market Share and Revenue (USD Million) for 2018-2030
      • 15.12.1.2 Ketamine
        • 15.12.1.2.1 Indonesia Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 15.12.1.3 MDMA
        • 15.12.1.3.1 Indonesia MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 15.12.1.4 Psilocybin
        • 15.12.1.4.1 Indonesia Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 15.12.1.5 DMT
        • 15.12.1.5.1 Indonesia DMT Market Share and Revenue (USD Million) for 2018-2030
      • 15.12.1.6 Ayahuasca
        • 15.12.1.6.1 Indonesia Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 15.12.1.7 LSD
        • 15.12.1.7.1 Indonesia LSD Market Share and Revenue (USD Million) for 2018-2030
      • 15.12.1.8 Other
        • 15.12.1.8.1 Indonesia Other Market Share and Revenue (USD Million) for 2018-2030
    • 15.12.2 Indonesia Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 15.12.2.1 Synthetic Substances
        • 15.12.2.1.1 Indonesia Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 15.12.2.2 Natural Substances
        • 15.12.2.2.1 Indonesia Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 15.12.3 Indonesia Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 15.12.3.1 Depression and Anxiety Disorders
        • 15.12.3.1.1 Indonesia Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.12.3.2 Pain Disorders
        • 15.12.3.2.1 Indonesia Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.12.3.3 Sleep-Related Disorders
        • 15.12.3.3.1 Indonesia Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.12.3.4 Trauma
        • 15.12.3.4.1 Indonesia Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 15.12.3.5 Other
        • 15.12.3.5.1 Indonesia Other Market Share and Revenue (USD Million) for 2018-2030
  • 15.13 Rest of APAC Psychedelic Therapeutics Market Size (2018-2030)
    • 15.13.1 Rest of APAC Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 15.13.1.1 GHB
        • 15.13.1.1.1 Rest of APAC GHB Market Share and Revenue (USD Million) for 2018-2030
      • 15.13.1.2 Ketamine
        • 15.13.1.2.1 Rest of APAC Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 15.13.1.3 MDMA
        • 15.13.1.3.1 Rest of APAC MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 15.13.1.4 Psilocybin
        • 15.13.1.4.1 Rest of APAC Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 15.13.1.5 DMT
        • 15.13.1.5.1 Rest of APAC DMT Market Share and Revenue (USD Million) for 2018-2030
      • 15.13.1.6 Ayahuasca
        • 15.13.1.6.1 Rest of APAC Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 15.13.1.7 LSD
        • 15.13.1.7.1 Rest of APAC LSD Market Share and Revenue (USD Million) for 2018-2030
      • 15.13.1.8 Other
        • 15.13.1.8.1 Rest of APAC Other Market Share and Revenue (USD Million) for 2018-2030
    • 15.13.2 Rest of APAC Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 15.13.2.1 Synthetic Substances
        • 15.13.2.1.1 Rest of APAC Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 15.13.2.2 Natural Substances
        • 15.13.2.2.1 Rest of APAC Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 15.13.3 Rest of APAC Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 15.13.3.1 Depression and Anxiety Disorders
        • 15.13.3.1.1 Rest of APAC Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.13.3.2 Pain Disorders
        • 15.13.3.2.1 Rest of APAC Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.13.3.3 Sleep-Related Disorders
        • 15.13.3.3.1 Rest of APAC Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 15.13.3.4 Trauma
        • 15.13.3.4.1 Rest of APAC Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 15.13.3.5 Other
        • 15.13.3.5.1 Rest of APAC Other Market Share and Revenue (USD Million) for 2018-2030
Chapter 16 Latin America Psychedelic Therapeutics Market Outlook (2018 - 2030)
  • 16.1 Latin America
    • 16.1.1 Latin America Psychedelic Therapeutics Market Trends and Analysis
    • 16.1.2 Latin America Psychedelic Therapeutics Market by Country, 2018-2030
    • 16.1.3 Latin America Psychedelic Therapeutics Market Attractiveness Analysis by Country
  • 16.2 Latin America Psychedelic Therapeutics Market Size (2018-2030)
    • 16.2.1 Latin America Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 16.2.1.1 GHB
        • 16.2.1.1.1 Latin America GHB Market Share and Revenue (USD Million) for 2018-2030
      • 16.2.1.2 Ketamine
        • 16.2.1.2.1 Latin America Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 16.2.1.3 MDMA
        • 16.2.1.3.1 Latin America MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 16.2.1.4 Psilocybin
        • 16.2.1.4.1 Latin America Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 16.2.1.5 DMT
        • 16.2.1.5.1 Latin America DMT Market Share and Revenue (USD Million) for 2018-2030
      • 16.2.1.6 Ayahuasca
        • 16.2.1.6.1 Latin America Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 16.2.1.7 LSD
        • 16.2.1.7.1 Latin America LSD Market Share and Revenue (USD Million) for 2018-2030
      • 16.2.1.8 Other
        • 16.2.1.8.1 Latin America Other Market Share and Revenue (USD Million) for 2018-2030
    • 16.2.2 Latin America Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 16.2.2.1 Synthetic Substances
        • 16.2.2.1.1 Latin America Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 16.2.2.2 Natural Substances
        • 16.2.2.2.1 Latin America Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 16.2.3 Latin America Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 16.2.3.1 Depression and Anxiety Disorders
        • 16.2.3.1.1 Latin America Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.2.3.2 Pain Disorders
        • 16.2.3.2.1 Latin America Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.2.3.3 Sleep-Related Disorders
        • 16.2.3.3.1 Latin America Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.2.3.4 Trauma
        • 16.2.3.4.1 Latin America Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 16.2.3.5 Other
        • 16.2.3.5.1 Latin America Other Market Share and Revenue (USD Million) for 2018-2030
  • 16.3 Brazil Psychedelic Therapeutics Market Size (2018-2030)
    • 16.3.1 Brazil Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 16.3.1.1 GHB
        • 16.3.1.1.1 Brazil GHB Market Share and Revenue (USD Million) for 2018-2030
      • 16.3.1.2 Ketamine
        • 16.3.1.2.1 Brazil Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 16.3.1.3 MDMA
        • 16.3.1.3.1 Brazil MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 16.3.1.4 Psilocybin
        • 16.3.1.4.1 Brazil Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 16.3.1.5 DMT
        • 16.3.1.5.1 Brazil DMT Market Share and Revenue (USD Million) for 2018-2030
      • 16.3.1.6 Ayahuasca
        • 16.3.1.6.1 Brazil Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 16.3.1.7 LSD
        • 16.3.1.7.1 Brazil LSD Market Share and Revenue (USD Million) for 2018-2030
      • 16.3.1.8 Other
        • 16.3.1.8.1 Brazil Other Market Share and Revenue (USD Million) for 2018-2030
    • 16.3.2 Brazil Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 16.3.2.1 Synthetic Substances
        • 16.3.2.1.1 Brazil Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 16.3.2.2 Natural Substances
        • 16.3.2.2.1 Brazil Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 16.3.3 Brazil Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 16.3.3.1 Depression and Anxiety Disorders
        • 16.3.3.1.1 Brazil Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.3.3.2 Pain Disorders
        • 16.3.3.2.1 Brazil Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.3.3.3 Sleep-Related Disorders
        • 16.3.3.3.1 Brazil Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.3.3.4 Trauma
        • 16.3.3.4.1 Brazil Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 16.3.3.5 Other
        • 16.3.3.5.1 Brazil Other Market Share and Revenue (USD Million) for 2018-2030
  • 16.4 Argentina Psychedelic Therapeutics Market Size (2018-2030)
    • 16.4.1 Argentina Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 16.4.1.1 GHB
        • 16.4.1.1.1 Argentina GHB Market Share and Revenue (USD Million) for 2018-2030
      • 16.4.1.2 Ketamine
        • 16.4.1.2.1 Argentina Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 16.4.1.3 MDMA
        • 16.4.1.3.1 Argentina MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 16.4.1.4 Psilocybin
        • 16.4.1.4.1 Argentina Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 16.4.1.5 DMT
        • 16.4.1.5.1 Argentina DMT Market Share and Revenue (USD Million) for 2018-2030
      • 16.4.1.6 Ayahuasca
        • 16.4.1.6.1 Argentina Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 16.4.1.7 LSD
        • 16.4.1.7.1 Argentina LSD Market Share and Revenue (USD Million) for 2018-2030
      • 16.4.1.8 Other
        • 16.4.1.8.1 Argentina Other Market Share and Revenue (USD Million) for 2018-2030
    • 16.4.2 Argentina Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 16.4.2.1 Synthetic Substances
        • 16.4.2.1.1 Argentina Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 16.4.2.2 Natural Substances
        • 16.4.2.2.1 Argentina Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 16.4.3 Argentina Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 16.4.3.1 Depression and Anxiety Disorders
        • 16.4.3.1.1 Argentina Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.4.3.2 Pain Disorders
        • 16.4.3.2.1 Argentina Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.4.3.3 Sleep-Related Disorders
        • 16.4.3.3.1 Argentina Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.4.3.4 Trauma
        • 16.4.3.4.1 Argentina Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 16.4.3.5 Other
        • 16.4.3.5.1 Argentina Other Market Share and Revenue (USD Million) for 2018-2030
  • 16.5 Colombia Psychedelic Therapeutics Market Size (2018-2030)
    • 16.5.1 Colombia Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 16.5.1.1 GHB
        • 16.5.1.1.1 Colombia GHB Market Share and Revenue (USD Million) for 2018-2030
      • 16.5.1.2 Ketamine
        • 16.5.1.2.1 Colombia Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 16.5.1.3 MDMA
        • 16.5.1.3.1 Colombia MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 16.5.1.4 Psilocybin
        • 16.5.1.4.1 Colombia Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 16.5.1.5 DMT
        • 16.5.1.5.1 Colombia DMT Market Share and Revenue (USD Million) for 2018-2030
      • 16.5.1.6 Ayahuasca
        • 16.5.1.6.1 Colombia Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 16.5.1.7 LSD
        • 16.5.1.7.1 Colombia LSD Market Share and Revenue (USD Million) for 2018-2030
      • 16.5.1.8 Other
        • 16.5.1.8.1 Colombia Other Market Share and Revenue (USD Million) for 2018-2030
    • 16.5.2 Colombia Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 16.5.2.1 Synthetic Substances
        • 16.5.2.1.1 Colombia Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 16.5.2.2 Natural Substances
        • 16.5.2.2.1 Colombia Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 16.5.3 Colombia Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 16.5.3.1 Depression and Anxiety Disorders
        • 16.5.3.1.1 Colombia Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.5.3.2 Pain Disorders
        • 16.5.3.2.1 Colombia Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.5.3.3 Sleep-Related Disorders
        • 16.5.3.3.1 Colombia Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.5.3.4 Trauma
        • 16.5.3.4.1 Colombia Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 16.5.3.5 Other
        • 16.5.3.5.1 Colombia Other Market Share and Revenue (USD Million) for 2018-2030
  • 16.6 Peru Psychedelic Therapeutics Market Size (2018-2030)
    • 16.6.1 Peru Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 16.6.1.1 GHB
        • 16.6.1.1.1 Peru GHB Market Share and Revenue (USD Million) for 2018-2030
      • 16.6.1.2 Ketamine
        • 16.6.1.2.1 Peru Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 16.6.1.3 MDMA
        • 16.6.1.3.1 Peru MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 16.6.1.4 Psilocybin
        • 16.6.1.4.1 Peru Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 16.6.1.5 DMT
        • 16.6.1.5.1 Peru DMT Market Share and Revenue (USD Million) for 2018-2030
      • 16.6.1.6 Ayahuasca
        • 16.6.1.6.1 Peru Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 16.6.1.7 LSD
        • 16.6.1.7.1 Peru LSD Market Share and Revenue (USD Million) for 2018-2030
      • 16.6.1.8 Other
        • 16.6.1.8.1 Peru Other Market Share and Revenue (USD Million) for 2018-2030
    • 16.6.2 Peru Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 16.6.2.1 Synthetic Substances
        • 16.6.2.1.1 Peru Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 16.6.2.2 Natural Substances
        • 16.6.2.2.1 Peru Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 16.6.3 Peru Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 16.6.3.1 Depression and Anxiety Disorders
        • 16.6.3.1.1 Peru Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.6.3.2 Pain Disorders
        • 16.6.3.2.1 Peru Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.6.3.3 Sleep-Related Disorders
        • 16.6.3.3.1 Peru Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.6.3.4 Trauma
        • 16.6.3.4.1 Peru Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 16.6.3.5 Other
        • 16.6.3.5.1 Peru Other Market Share and Revenue (USD Million) for 2018-2030
  • 16.7 Chile Psychedelic Therapeutics Market Size (2018-2030)
    • 16.7.1 Chile Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 16.7.1.1 GHB
        • 16.7.1.1.1 Chile GHB Market Share and Revenue (USD Million) for 2018-2030
      • 16.7.1.2 Ketamine
        • 16.7.1.2.1 Chile Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 16.7.1.3 MDMA
        • 16.7.1.3.1 Chile MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 16.7.1.4 Psilocybin
        • 16.7.1.4.1 Chile Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 16.7.1.5 DMT
        • 16.7.1.5.1 Chile DMT Market Share and Revenue (USD Million) for 2018-2030
      • 16.7.1.6 Ayahuasca
        • 16.7.1.6.1 Chile Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 16.7.1.7 LSD
        • 16.7.1.7.1 Chile LSD Market Share and Revenue (USD Million) for 2018-2030
      • 16.7.1.8 Other
        • 16.7.1.8.1 Chile Other Market Share and Revenue (USD Million) for 2018-2030
    • 16.7.2 Chile Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 16.7.2.1 Synthetic Substances
        • 16.7.2.1.1 Chile Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 16.7.2.2 Natural Substances
        • 16.7.2.2.1 Chile Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 16.7.3 Chile Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 16.7.3.1 Depression and Anxiety Disorders
        • 16.7.3.1.1 Chile Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.7.3.2 Pain Disorders
        • 16.7.3.2.1 Chile Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.7.3.3 Sleep-Related Disorders
        • 16.7.3.3.1 Chile Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.7.3.4 Trauma
        • 16.7.3.4.1 Chile Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 16.7.3.5 Other
        • 16.7.3.5.1 Chile Other Market Share and Revenue (USD Million) for 2018-2030
  • 16.8 Rest of South America Psychedelic Therapeutics Market Size (2018-2030)
    • 16.8.1 Rest of South America Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 16.8.1.1 GHB
        • 16.8.1.1.1 Rest of South America GHB Market Share and Revenue (USD Million) for 2018-2030
      • 16.8.1.2 Ketamine
        • 16.8.1.2.1 Rest of South America Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 16.8.1.3 MDMA
        • 16.8.1.3.1 Rest of South America MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 16.8.1.4 Psilocybin
        • 16.8.1.4.1 Rest of South America Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 16.8.1.5 DMT
        • 16.8.1.5.1 Rest of South America DMT Market Share and Revenue (USD Million) for 2018-2030
      • 16.8.1.6 Ayahuasca
        • 16.8.1.6.1 Rest of South America Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 16.8.1.7 LSD
        • 16.8.1.7.1 Rest of South America LSD Market Share and Revenue (USD Million) for 2018-2030
      • 16.8.1.8 Other
        • 16.8.1.8.1 Rest of South America Other Market Share and Revenue (USD Million) for 2018-2030
    • 16.8.2 Rest of South America Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 16.8.2.1 Synthetic Substances
        • 16.8.2.1.1 Rest of South America Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 16.8.2.2 Natural Substances
        • 16.8.2.2.1 Rest of South America Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 16.8.3 Rest of South America Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 16.8.3.1 Depression and Anxiety Disorders
        • 16.8.3.1.1 Rest of South America Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.8.3.2 Pain Disorders
        • 16.8.3.2.1 Rest of South America Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.8.3.3 Sleep-Related Disorders
        • 16.8.3.3.1 Rest of South America Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 16.8.3.4 Trauma
        • 16.8.3.4.1 Rest of South America Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 16.8.3.5 Other
        • 16.8.3.5.1 Rest of South America Other Market Share and Revenue (USD Million) for 2018-2030
Chapter 17 Middle East and Africa Psychedelic Therapeutics Market Outlook (2018 - 2030)
  • 17.1 Middle East and Africa
    • 17.1.1 Middle East and Africa Psychedelic Therapeutics Market Trends and Analysis
    • 17.1.2 Middle East and Africa Psychedelic Therapeutics Market by Country, 2018-2030
    • 17.1.3 Middle East and Africa Psychedelic Therapeutics Market Attractiveness Analysis by Country
  • 17.2 Middle East and Africa Psychedelic Therapeutics Market Size (2018-2030)
    • 17.2.1 Middle East and Africa Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 17.2.1.1 GHB
        • 17.2.1.1.1 Middle East and Africa GHB Market Share and Revenue (USD Million) for 2018-2030
      • 17.2.1.2 Ketamine
        • 17.2.1.2.1 Middle East and Africa Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 17.2.1.3 MDMA
        • 17.2.1.3.1 Middle East and Africa MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 17.2.1.4 Psilocybin
        • 17.2.1.4.1 Middle East and Africa Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 17.2.1.5 DMT
        • 17.2.1.5.1 Middle East and Africa DMT Market Share and Revenue (USD Million) for 2018-2030
      • 17.2.1.6 Ayahuasca
        • 17.2.1.6.1 Middle East and Africa Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 17.2.1.7 LSD
        • 17.2.1.7.1 Middle East and Africa LSD Market Share and Revenue (USD Million) for 2018-2030
      • 17.2.1.8 Other
        • 17.2.1.8.1 Middle East and Africa Other Market Share and Revenue (USD Million) for 2018-2030
    • 17.2.2 Middle East and Africa Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 17.2.2.1 Synthetic Substances
        • 17.2.2.1.1 Middle East and Africa Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 17.2.2.2 Natural Substances
        • 17.2.2.2.1 Middle East and Africa Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 17.2.3 Middle East and Africa Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 17.2.3.1 Depression and Anxiety Disorders
        • 17.2.3.1.1 Middle East and Africa Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.2.3.2 Pain Disorders
        • 17.2.3.2.1 Middle East and Africa Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.2.3.3 Sleep-Related Disorders
        • 17.2.3.3.1 Middle East and Africa Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.2.3.4 Trauma
        • 17.2.3.4.1 Middle East and Africa Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 17.2.3.5 Other
        • 17.2.3.5.1 Middle East and Africa Other Market Share and Revenue (USD Million) for 2018-2030
  • 17.3 Saudi Arabia Psychedelic Therapeutics Market Size (2018-2030)
    • 17.3.1 Saudi Arabia Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 17.3.1.1 GHB
        • 17.3.1.1.1 Saudi Arabia GHB Market Share and Revenue (USD Million) for 2018-2030
      • 17.3.1.2 Ketamine
        • 17.3.1.2.1 Saudi Arabia Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 17.3.1.3 MDMA
        • 17.3.1.3.1 Saudi Arabia MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 17.3.1.4 Psilocybin
        • 17.3.1.4.1 Saudi Arabia Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 17.3.1.5 DMT
        • 17.3.1.5.1 Saudi Arabia DMT Market Share and Revenue (USD Million) for 2018-2030
      • 17.3.1.6 Ayahuasca
        • 17.3.1.6.1 Saudi Arabia Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 17.3.1.7 LSD
        • 17.3.1.7.1 Saudi Arabia LSD Market Share and Revenue (USD Million) for 2018-2030
      • 17.3.1.8 Other
        • 17.3.1.8.1 Saudi Arabia Other Market Share and Revenue (USD Million) for 2018-2030
    • 17.3.2 Saudi Arabia Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 17.3.2.1 Synthetic Substances
        • 17.3.2.1.1 Saudi Arabia Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 17.3.2.2 Natural Substances
        • 17.3.2.2.1 Saudi Arabia Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 17.3.3 Saudi Arabia Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 17.3.3.1 Depression and Anxiety Disorders
        • 17.3.3.1.1 Saudi Arabia Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.3.3.2 Pain Disorders
        • 17.3.3.2.1 Saudi Arabia Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.3.3.3 Sleep-Related Disorders
        • 17.3.3.3.1 Saudi Arabia Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.3.3.4 Trauma
        • 17.3.3.4.1 Saudi Arabia Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 17.3.3.5 Other
        • 17.3.3.5.1 Saudi Arabia Other Market Share and Revenue (USD Million) for 2018-2030
  • 17.4 Turkey Psychedelic Therapeutics Market Size (2018-2030)
    • 17.4.1 Turkey Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 17.4.1.1 GHB
        • 17.4.1.1.1 Turkey GHB Market Share and Revenue (USD Million) for 2018-2030
      • 17.4.1.2 Ketamine
        • 17.4.1.2.1 Turkey Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 17.4.1.3 MDMA
        • 17.4.1.3.1 Turkey MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 17.4.1.4 Psilocybin
        • 17.4.1.4.1 Turkey Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 17.4.1.5 DMT
        • 17.4.1.5.1 Turkey DMT Market Share and Revenue (USD Million) for 2018-2030
      • 17.4.1.6 Ayahuasca
        • 17.4.1.6.1 Turkey Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 17.4.1.7 LSD
        • 17.4.1.7.1 Turkey LSD Market Share and Revenue (USD Million) for 2018-2030
      • 17.4.1.8 Other
        • 17.4.1.8.1 Turkey Other Market Share and Revenue (USD Million) for 2018-2030
    • 17.4.2 Turkey Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 17.4.2.1 Synthetic Substances
        • 17.4.2.1.1 Turkey Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 17.4.2.2 Natural Substances
        • 17.4.2.2.1 Turkey Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 17.4.3 Turkey Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 17.4.3.1 Depression and Anxiety Disorders
        • 17.4.3.1.1 Turkey Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.4.3.2 Pain Disorders
        • 17.4.3.2.1 Turkey Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.4.3.3 Sleep-Related Disorders
        • 17.4.3.3.1 Turkey Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.4.3.4 Trauma
        • 17.4.3.4.1 Turkey Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 17.4.3.5 Other
        • 17.4.3.5.1 Turkey Other Market Share and Revenue (USD Million) for 2018-2030
  • 17.5 Nigeria Psychedelic Therapeutics Market Size (2018-2030)
    • 17.5.1 Nigeria Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 17.5.1.1 GHB
        • 17.5.1.1.1 Nigeria GHB Market Share and Revenue (USD Million) for 2018-2030
      • 17.5.1.2 Ketamine
        • 17.5.1.2.1 Nigeria Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 17.5.1.3 MDMA
        • 17.5.1.3.1 Nigeria MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 17.5.1.4 Psilocybin
        • 17.5.1.4.1 Nigeria Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 17.5.1.5 DMT
        • 17.5.1.5.1 Nigeria DMT Market Share and Revenue (USD Million) for 2018-2030
      • 17.5.1.6 Ayahuasca
        • 17.5.1.6.1 Nigeria Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 17.5.1.7 LSD
        • 17.5.1.7.1 Nigeria LSD Market Share and Revenue (USD Million) for 2018-2030
      • 17.5.1.8 Other
        • 17.5.1.8.1 Nigeria Other Market Share and Revenue (USD Million) for 2018-2030
    • 17.5.2 Nigeria Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 17.5.2.1 Synthetic Substances
        • 17.5.2.1.1 Nigeria Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 17.5.2.2 Natural Substances
        • 17.5.2.2.1 Nigeria Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 17.5.3 Nigeria Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 17.5.3.1 Depression and Anxiety Disorders
        • 17.5.3.1.1 Nigeria Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.5.3.2 Pain Disorders
        • 17.5.3.2.1 Nigeria Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.5.3.3 Sleep-Related Disorders
        • 17.5.3.3.1 Nigeria Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.5.3.4 Trauma
        • 17.5.3.4.1 Nigeria Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 17.5.3.5 Other
        • 17.5.3.5.1 Nigeria Other Market Share and Revenue (USD Million) for 2018-2030
  • 17.6 UAE Psychedelic Therapeutics Market Size (2018-2030)
    • 17.6.1 UAE Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 17.6.1.1 GHB
        • 17.6.1.1.1 UAE GHB Market Share and Revenue (USD Million) for 2018-2030
      • 17.6.1.2 Ketamine
        • 17.6.1.2.1 UAE Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 17.6.1.3 MDMA
        • 17.6.1.3.1 UAE MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 17.6.1.4 Psilocybin
        • 17.6.1.4.1 UAE Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 17.6.1.5 DMT
        • 17.6.1.5.1 UAE DMT Market Share and Revenue (USD Million) for 2018-2030
      • 17.6.1.6 Ayahuasca
        • 17.6.1.6.1 UAE Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 17.6.1.7 LSD
        • 17.6.1.7.1 UAE LSD Market Share and Revenue (USD Million) for 2018-2030
      • 17.6.1.8 Other
        • 17.6.1.8.1 UAE Other Market Share and Revenue (USD Million) for 2018-2030
    • 17.6.2 UAE Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 17.6.2.1 Synthetic Substances
        • 17.6.2.1.1 UAE Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 17.6.2.2 Natural Substances
        • 17.6.2.2.1 UAE Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 17.6.3 UAE Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 17.6.3.1 Depression and Anxiety Disorders
        • 17.6.3.1.1 UAE Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.6.3.2 Pain Disorders
        • 17.6.3.2.1 UAE Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.6.3.3 Sleep-Related Disorders
        • 17.6.3.3.1 UAE Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.6.3.4 Trauma
        • 17.6.3.4.1 UAE Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 17.6.3.5 Other
        • 17.6.3.5.1 UAE Other Market Share and Revenue (USD Million) for 2018-2030
  • 17.7 Egypt Psychedelic Therapeutics Market Size (2018-2030)
    • 17.7.1 Egypt Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 17.7.1.1 GHB
        • 17.7.1.1.1 Egypt GHB Market Share and Revenue (USD Million) for 2018-2030
      • 17.7.1.2 Ketamine
        • 17.7.1.2.1 Egypt Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 17.7.1.3 MDMA
        • 17.7.1.3.1 Egypt MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 17.7.1.4 Psilocybin
        • 17.7.1.4.1 Egypt Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 17.7.1.5 DMT
        • 17.7.1.5.1 Egypt DMT Market Share and Revenue (USD Million) for 2018-2030
      • 17.7.1.6 Ayahuasca
        • 17.7.1.6.1 Egypt Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 17.7.1.7 LSD
        • 17.7.1.7.1 Egypt LSD Market Share and Revenue (USD Million) for 2018-2030
      • 17.7.1.8 Other
        • 17.7.1.8.1 Egypt Other Market Share and Revenue (USD Million) for 2018-2030
    • 17.7.2 Egypt Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 17.7.2.1 Synthetic Substances
        • 17.7.2.1.1 Egypt Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 17.7.2.2 Natural Substances
        • 17.7.2.2.1 Egypt Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 17.7.3 Egypt Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 17.7.3.1 Depression and Anxiety Disorders
        • 17.7.3.1.1 Egypt Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.7.3.2 Pain Disorders
        • 17.7.3.2.1 Egypt Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.7.3.3 Sleep-Related Disorders
        • 17.7.3.3.1 Egypt Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.7.3.4 Trauma
        • 17.7.3.4.1 Egypt Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 17.7.3.5 Other
        • 17.7.3.5.1 Egypt Other Market Share and Revenue (USD Million) for 2018-2030
  • 17.8 South Africa Psychedelic Therapeutics Market Size (2018-2030)
    • 17.8.1 South Africa Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 17.8.1.1 GHB
        • 17.8.1.1.1 South Africa GHB Market Share and Revenue (USD Million) for 2018-2030
      • 17.8.1.2 Ketamine
        • 17.8.1.2.1 South Africa Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 17.8.1.3 MDMA
        • 17.8.1.3.1 South Africa MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 17.8.1.4 Psilocybin
        • 17.8.1.4.1 South Africa Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 17.8.1.5 DMT
        • 17.8.1.5.1 South Africa DMT Market Share and Revenue (USD Million) for 2018-2030
      • 17.8.1.6 Ayahuasca
        • 17.8.1.6.1 South Africa Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 17.8.1.7 LSD
        • 17.8.1.7.1 South Africa LSD Market Share and Revenue (USD Million) for 2018-2030
      • 17.8.1.8 Other
        • 17.8.1.8.1 South Africa Other Market Share and Revenue (USD Million) for 2018-2030
    • 17.8.2 South Africa Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 17.8.2.1 Synthetic Substances
        • 17.8.2.1.1 South Africa Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 17.8.2.2 Natural Substances
        • 17.8.2.2.1 South Africa Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 17.8.3 South Africa Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 17.8.3.1 Depression and Anxiety Disorders
        • 17.8.3.1.1 South Africa Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.8.3.2 Pain Disorders
        • 17.8.3.2.1 South Africa Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.8.3.3 Sleep-Related Disorders
        • 17.8.3.3.1 South Africa Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.8.3.4 Trauma
        • 17.8.3.4.1 South Africa Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 17.8.3.5 Other
        • 17.8.3.5.1 South Africa Other Market Share and Revenue (USD Million) for 2018-2030
  • 17.9 GCC Countries Psychedelic Therapeutics Market Size (2018-2030)
    • 17.9.1 GCC Countries Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 17.9.1.1 GHB
        • 17.9.1.1.1 GCC Countries GHB Market Share and Revenue (USD Million) for 2018-2030
      • 17.9.1.2 Ketamine
        • 17.9.1.2.1 GCC Countries Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 17.9.1.3 MDMA
        • 17.9.1.3.1 GCC Countries MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 17.9.1.4 Psilocybin
        • 17.9.1.4.1 GCC Countries Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 17.9.1.5 DMT
        • 17.9.1.5.1 GCC Countries DMT Market Share and Revenue (USD Million) for 2018-2030
      • 17.9.1.6 Ayahuasca
        • 17.9.1.6.1 GCC Countries Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 17.9.1.7 LSD
        • 17.9.1.7.1 GCC Countries LSD Market Share and Revenue (USD Million) for 2018-2030
      • 17.9.1.8 Other
        • 17.9.1.8.1 GCC Countries Other Market Share and Revenue (USD Million) for 2018-2030
    • 17.9.2 GCC Countries Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 17.9.2.1 Synthetic Substances
        • 17.9.2.1.1 GCC Countries Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 17.9.2.2 Natural Substances
        • 17.9.2.2.1 GCC Countries Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 17.9.3 GCC Countries Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 17.9.3.1 Depression and Anxiety Disorders
        • 17.9.3.1.1 GCC Countries Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.9.3.2 Pain Disorders
        • 17.9.3.2.1 GCC Countries Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.9.3.3 Sleep-Related Disorders
        • 17.9.3.3.1 GCC Countries Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.9.3.4 Trauma
        • 17.9.3.4.1 GCC Countries Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 17.9.3.5 Other
        • 17.9.3.5.1 GCC Countries Other Market Share and Revenue (USD Million) for 2018-2030
  • 17.10 Rest of MEA Psychedelic Therapeutics Market Size (2018-2030)
    • 17.10.1 Rest of MEA Psychedelic Therapeutics Market (USD Million) by Type (2018-2030)
      • 17.10.1.1 GHB
        • 17.10.1.1.1 Rest of MEA GHB Market Share and Revenue (USD Million) for 2018-2030
      • 17.10.1.2 Ketamine
        • 17.10.1.2.1 Rest of MEA Ketamine Market Share and Revenue (USD Million) for 2018-2030
      • 17.10.1.3 MDMA
        • 17.10.1.3.1 Rest of MEA MDMA Market Share and Revenue (USD Million) for 2018-2030
      • 17.10.1.4 Psilocybin
        • 17.10.1.4.1 Rest of MEA Psilocybin Market Share and Revenue (USD Million) for 2018-2030
      • 17.10.1.5 DMT
        • 17.10.1.5.1 Rest of MEA DMT Market Share and Revenue (USD Million) for 2018-2030
      • 17.10.1.6 Ayahuasca
        • 17.10.1.6.1 Rest of MEA Ayahuasca Market Share and Revenue (USD Million) for 2018-2030
      • 17.10.1.7 LSD
        • 17.10.1.7.1 Rest of MEA LSD Market Share and Revenue (USD Million) for 2018-2030
      • 17.10.1.8 Other
        • 17.10.1.8.1 Rest of MEA Other Market Share and Revenue (USD Million) for 2018-2030
    • 17.10.2 Rest of MEA Psychedelic Therapeutics Market (USD Million) by Origin of Psychedelic Substance (2018-2030)
      • 17.10.2.1 Synthetic Substances
        • 17.10.2.1.1 Rest of MEA Synthetic Substances Market Share and Revenue (USD Million) for 2018-2030
      • 17.10.2.2 Natural Substances
        • 17.10.2.2.1 Rest of MEA Natural Substances Market Share and Revenue (USD Million) for 2018-2030
    • 17.10.3 Rest of MEA Psychedelic Therapeutics Market (USD Million) by Target Therapeutic Area (2018-2030)
      • 17.10.3.1 Depression and Anxiety Disorders
        • 17.10.3.1.1 Rest of MEA Depression and Anxiety Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.10.3.2 Pain Disorders
        • 17.10.3.2.1 Rest of MEA Pain Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.10.3.3 Sleep-Related Disorders
        • 17.10.3.3.1 Rest of MEA Sleep-Related Disorders Market Share and Revenue (USD Million) for 2018-2030
      • 17.10.3.4 Trauma
        • 17.10.3.4.1 Rest of MEA Trauma Market Share and Revenue (USD Million) for 2018-2030
      • 17.10.3.5 Other
        • 17.10.3.5.1 Rest of MEA Other Market Share and Revenue (USD Million) for 2018-2030

This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Psychedelic Therapeutics market

Chapter 18 Research Findings
  • 18.1 Key Takeaways
  • 18.2 Analyst Point of View

We not only deliver the published report but only provide customized data on request to make your customized report edition (Exclusively Delivered and not shared on the website/Other Clients). The following additional data and delivery depend on Data Availability, Client's Data Request, Additional Charges Applied, etc.

Customize the Report Edition (Is applicable, On Request, Subject to Data Available, At an Additional Cost)
Segmentation Level Customization
  • Additional Segments and Sub Segment
  • Cross-split Segments of Psychedelic Therapeutics
  • Additional Countries Granular data
    		•
    Global level Data Customization
  • Sales Volume
  • Production
  • Production Capacity
  • Pricing Analysis of Product
    		•
    Region level Data Customization
  • Sales Volume
  • Production
  • Production Capacity
  • Pricing Analysis of Product
    		•
    Country level Data Customization
  • Sales Volume
  • Production
  • Production Capacity
  • Segment Analysis on Country level is also available (On request)
  • Pricing Analysis of Product
    		•
    Company Level
  • Company Market Share on Regional Level/ Country Level
  • Company Sales Volume
  • Company Production Volume
  • Company Production Capacity
  • Company Specific Distributors
  • Manufacturing Process by different manufacturers
  • Global/ Regional/ Country level Major Distributors
  • Additional Competitors Analysis of your choice
  • Tier 1 tier 2 tier 3 start ups....
  • Manufacturers Market Concentration Ratio
  • Industry benchmarking
    		•
    Additional Data Analysis
  • Surveys/polls
  • Value Chain Analysis
  • Raw Material Analysis
  • Price Trend Analysis
  • Supplier/Distributor List
  • Market Economic
  • Supply Demand Gap Analysis
  • Customer Sentiment Analysis
  • Stock Price Prediction Analysis
  • Stock Performance Correlation Analysis
  • Patent Analysis
  • Technology Development Analysis
  • Merger and Acquistion Consulting
  • Top Winning Strategies / Strategic Benchmarkeing
  • Heat Map Analysis
  • ESG Analysis
  • Product life cycle
  • Customer buying behavior and decision-making process
  • Marketing Mix Analysis
  • Product Launch Strategy Building
    		•
    Additional Qualitative Data
  • Pipeline Products
  • Market Trends
  • Industry Events and Developments
  • Sales Key Indicators
  • Risk Analysis
  • Regulatory Landscape
  • Customer Sentiment Analysis
  • R&D landscape
  • Market Entry / Exit Consulting
  • Identifying New Application/End Use
    		•
    Additional Quantitative Data
  • Import Data
  • Export Data
  • Quarterly Revenue (Q1,Q2,Q3,Q4)
  • Forecast Period Extension: 2023 to 2033
  • Historical Period Data Available: 2011 to 2022
  • IPO prospectus
    		•
    Service Level Customization
  • Quarterly Report Updates (Q1,Q2,Q3,Q4)
  • Annual Report Updates (Subscribe 1/2/3/4/...Years)
  • Exclusive Report Delivery (NDA)
  • Dedicated Research Analyst Support (Email, Calls, Interview)
  • Data Support (Unlimited Time Period)
  • Psychedelic Therapeutics Database Subscription (Full Access)
    		•
    Report Format Alteration
  • Quarterly Revenue (Q1,Q2,Q3,Q4)
  • Revenue in USD ($)/Euro (€)/Pound (£)/Yen (¥)/etc
  • Translation Rights and Multi Language Report Editions
  • Average FOB Price/Average Selling Price
    		•

    We have various report editions of Psychedelic Therapeutics Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

    Psychedelic Therapeutics Market Analysis

    Global Psychedelic Therapeutics Market Report 2023 talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Psychedelic Therapeutics Industry growth. Psychedelic Therapeutics market has been segmented with the help of its Type, Origin of Psychedelic Substance Target Therapeutic Area, and others. Psychedelic Therapeutics market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.

    Report scope is customizable as we have a huge database of Psychedelic Therapeutics industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.

    Industry segmentation can be altred as per your needs. For example, we can proivde cross slipt between GHB with Origin of Psychedelic Substance, Target Therapeutic Area, additional country analysis, volume/consumption data, etc.

    Psychedelic Therapeutics Market Report Scope
    Major Type Analysed
  • GHB
  • Ketamine
  • MDMA
  • Psilocybin
  • DMT
  • Ayahuasca
  • LSD
  • Other
    		•
    Major Origin of Psychedelic Substance Analysed
  • Synthetic Substances
  • Natural Substances
    		•
    Major Target Therapeutic Area Analysed Depression and Anxiety Disorders, Pain Disorders, Sleep-Related Disorders, Trauma, Other
    Top Manufacturers Disclosed
  • Celon Pharma Sa
  • Maps Public Benefit
  • Mindmed
  • Janssen Pharmaceuticals
  • Ix Biopharma Ltd
  • Jazz Pharmaceutical
  • Avadel
  • Pharmaceuticals Plc
  • Neurorx Inc
  • Douglas Pharmaceuticals Limited
  • The Emmes
  • Company Llc
  • Caamtech
  • Compass Pathways Plc
  • Eleusis Benefit Corporation
  • Awakn Life Sciences Inc
  • Psilera Bioscience
  • Braxia Scientific Corp
  • Mindset Pharma
  • Betterlife Pharma
  • Cybin
  • Cb Therapeutics
  • Numinus Wellness
  • Mydecine Innovations Group
  • Optimi Health
  • Pharmather
  • Field Trip Health
  • Atai Life Sciences
  • Gh Research
  • Seelos Therapeutics
  • Small Pharma
  • Bright Minds Biosciences Incannex Health
  • Psybio Therapeutics
  • Universal Ibogaine
  • Levitee Labs
  • Mind Cure Health
  • Novamind
  • Clearmind Medicine
  • Mynd Life Science
  • Wesana Health
  • Psyched Wellness
  • Havn Life Sciences
  • Tryp Therapeutics
  • Psyence Group
  • Silo Pharma
  • Core One Labs
  • M2Bio Sciences
  • Neonmind Biosciences
  • Delic Corp
  • Nova Mentis Life Science
  • Beckley Psytech
  • Delix Therapeutics
  • Diamond Therapeutics
  • Tactogen
  • Psygen Labs Inc
  • Bexson Biomedical
  • Eleusis Biotech
  • Psilera Biosceince
  • Octarine Bio
  • Heading Health
  • Maps Public Benefit Corporation (Pbc)
  • Aphrodite Health
  • Terran Biosciences
  • Mycrodose Therapeutics
  • Reset Pharma
  • Clerkenwell Health
  • Alvarius Pharmaceuticals
  • Ceruvia Lifesciences
  • Confidential Data
  • Access The Paid Version
  • Data Hidden
    • List of 2nd tier, 3rd tier and new players (data available)
  • Please Note: Not all players are disclosed | Listed In No particular Order due to Data Confidentiality
    		•
    Global, Regional and Country Analysis
  • North America (United States, Canada, Mexico)
  • Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
  • Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
  • South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
  • Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
    • Key Qualitative Information Covered
  • Drivers
  • Restraints
  • Opportunities
  • COVID-19 Impact Analysis
  • Key Trends
  • Technological Advancement

    • Type Segment Analysis of Psychedelic Therapeutics Market

    Based on present and future trends, the market size is estimated from 2018 to 2030. Moreover, study also provides quantitative and qualitative analysis of each type to understand the driving factors for the fastest growing type segment for Psychedelic Therapeutics market.

    Type of Psychedelic Therapeutics analyzed in this report are as follows:

    • GHB
    • Ketamine
    • MDMA
    • Psilocybin
    • DMT
    • Ayahuasca
    • LSD
    • Other

    Psychedelic Therapeutics Market Share (%) by Type in 2018-2030

    The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Psychedelic Therapeutics Industry. Request a Free Sample PDF!

    Origin of Psychedelic Substance Segment Analysis of Psychedelic Therapeutics Market

    This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities for each application of Psychedelic Therapeutics from 2018 to 2030. This will also help to analyze the demand for Psychedelic Therapeutics across different end-use industries. Our research team will also help acquire additional data such as Value Chain, Patent analysis, Company Evaluation Quadrant (Matrix), and much more confidential analysis and data insights.

    Some of the key Origin of Psychedelic Substance of Psychedelic Therapeutics are:

    • Synthetic Substances
    • Natural Substances

    Psychedelic Therapeutics Market Share (%) by Origin of Psychedelic Substance in 2018-2030

    The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Psychedelic Therapeutics market report 2023 Edition by contacting our team.

    Psychedelic Therapeutics Target Therapeutic Area Segment Analysis

    • Depression and Anxiety Disorders
    • Pain Disorders
    • Sleep-Related Disorders
    • Trauma
    • Other

    Psychedelic Therapeutics Market Regional Analysis

    Region and country analysis section of Psychedelic Therapeutics Industry Analysis has been segmented into 5 major region such as North America, Europe, Asia Pacific, Middle East & Africa ,and Latin America (along with respective major contributing countries) and provides the revenue share, current trends.

    The base years considered for all the estimations by analyzing trends and growth rate will help you gain an in-depth understanding of the conclusions provided in this report. This report also includes figures, graphs, pie charts, tables and bar graphs that explain the data analysis based on current trends at the country level as well as key regions. This research report also focuses on assessing factors such as profit, product price, capacity, production, supply demand market growth rate along with others to create a clear picture on the future prospects of Psychedelic Therapeutics market.

    Region-wise, the market is analyzed across: (In case you wish to acquire a specific region or any country data then please contact us)

    • North America (United States, Canada, Mexico)
    • Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
    • Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
    • South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
    • Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

    Psychedelic Therapeutics Market Share (%) by Region (2018-2030)

    The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!

    The base years considered for all the estimations by analyzing trends and growth rate will help you gain an in-depth understanding of the conclusions provided in this report. This report also includes figures, graphs, pie charts, tables and bar graphs that explain the data analysis based on current trends at the country level as well as key regions. This research report also focuses on assessing factors such as profit, product price, capacity, production, supply demand market growth rate along with others to create a clear picture on the future prospects of this market.

    Top Companies in Psychedelic Therapeutics Market

    Competitive Landscape includes company profiling of the key manufacturers listed below. It also provides the key developments such as new product launches, expansion, mergers & acquisitions, partnerships, agreements, joint ventures, business overview, key strategies and financial analysis associated with the key players. Strategy implemented to overcome the COVID-19 Impact will be discussed in the report scope. Key players Financials includes Revenue (USD Million), Gross Margin (%) and Market Share (%) (2018- 2022), S.W.O.T Analysis, (To read more request the sample pages Or speak to analyst/author directly).

    Top Companies Market Share in Psychedelic Therapeutics Industry: (In no particular order of Rank)

    • Celon Pharma Sa
    • Maps Public Benefit
    • Mindmed
    • Janssen Pharmaceuticals
    • Ix Biopharma Ltd
    • Jazz Pharmaceutical
    • Avadel
    • Pharmaceuticals Plc
    • Neurorx Inc
    • Douglas Pharmaceuticals Limited
    • The Emmes
    • Company Llc
    • Caamtech
    • Compass Pathways Plc
    • Eleusis Benefit Corporation
    • Awakn Life Sciences Inc
    • Psilera Bioscience
    • Braxia Scientific Corp
    • Mindset Pharma
    • Betterlife Pharma
    • Cybin
    • Cb Therapeutics
    • Numinus Wellness
    • Mydecine Innovations Group
    • Optimi Health
    • Pharmather
    • Field Trip Health
    • Atai Life Sciences
    • Gh Research
    • Seelos Therapeutics
    • Small Pharma
    • Bright Minds Biosciences Incannex Health
    • Psybio Therapeutics
    • Universal Ibogaine
    • Levitee Labs
    • Mind Cure Health
    • Novamind
    • Clearmind Medicine
    • Mynd Life Science
    • Wesana Health
    • Psyched Wellness
    • Havn Life Sciences
    • Tryp Therapeutics
    • Psyence Group
    • Silo Pharma
    • Core One Labs
    • M2Bio Sciences
    • Neonmind Biosciences
    • Delic Corp
    • Nova Mentis Life Science
    • Beckley Psytech
    • Delix Therapeutics
    • Diamond Therapeutics
    • Tactogen
    • Psygen Labs Inc
    • Bexson Biomedical
    • Eleusis Biotech
    • Psilera Biosceince
    • Octarine Bio
    • Heading Health
    • Maps Public Benefit Corporation (Pbc)
    • Aphrodite Health
    • Terran Biosciences
    • Mycrodose Therapeutics
    • Reset Pharma
    • Clerkenwell Health
    • Alvarius Pharmaceuticals
    • Ceruvia Lifesciences
    • Confidential Data
    • Access The Paid Version
    • Data Hidden
    *List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

    If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables..

    Author's Conclusion

    Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

    The Global Psychedelic Therapeutics Market is witnessing significant growth in the near future.

    In 2022, the GHB segment accounted for noticeable share of global Psychedelic Therapeutics Market and is projected to experience significant growth in the near future.

    The Synthetic Substances segment is expected to expand at the significant CAGR retaining position throughout the forecast period.

    Some of the key companies Celon Pharma Sa, Mindmed and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.

    Author's Detail

    Surabhi Bhaiyya, LinkedIn

    Senior Research Analyst at Cognitive Market Research

    Surabhi Bhaiyya is an experienced market researcher focused on the Pharma & Healthcare industry. With over 7+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry. To get in touch and access the above report book an apointment at https://calendly.com/speak-to-analyst.

    Research Methodology Implemented by Author

    • 1.1 Primary Research for Psychedelic Therapeutics Market
      • 1.1.1 Modes of Primary Research:
    • 1.2 Secondary Research for Psychedelic Therapeutics Market
    • 1.3 Market Estimation for Psychedelic Therapeutics Market
    • 1.4 Data Triangulation for Psychedelic Therapeutics Market
    • 1.5 Questionnaire for Psychedelic Therapeutics Market
    Preview Full Research Methodology

    Key Questions Answered By Psychedelic Therapeutics Market Report 2023

    Why GHB have a significant impact on Psychedelic Therapeutics market?
    What are the key factors affecting the GHB and Ketamine of Psychedelic Therapeutics Market?
    What is the CAGR/Growth Rate of Synthetic Substances during the forecast period?
    By type, which segment accounted for largest share of the global Psychedelic Therapeutics Market?
    Which region is expected to dominate the global Psychedelic Therapeutics Market within the forecast period?

    Frequently Asked Questions

    What is Psychedelic Therapeutics market size/share and growth rate?
    Psychedelic Therapeutics market size and its growth rate has been provided in the report. The historical period included in the report is from 2018 to 2022, whereas, the report provides forecast data for the years 2023 to 2030. This will help you to in terms of global market share, regional market share, country level market share to understand how the market has been performing in the past and how it is going to perform in the following years. Correspondingly, historical and forecast analysis comprises sales and revenue data of the global Psychedelic Therapeutics market. Market size for UK, Europe, North America, Asia Pacific, Middle East & Africa is also included in the report.
    What are the major factors affecting the Psychedelic Therapeutics market?
    The major factors affecting the Psychedelic Therapeutics market in a positive, as well as negative perspective, have been provided with detailed analysis in the report. This segment has encompassed drivers, opportunities, and challenges faced by the industry. This will help you to understand the major factors impacting Psychedelic Therapeutics market trends and develop your business strategy accordingly.
    Who are the top manufacturers of Psychedelic Therapeutics? List of Psychedelic Therapeutics Companies and there market trend or market share?
    Major manufacturers or list of Psychedelic Therapeutics manufacturers 2023 involved in the market have been profiled in the report along with their business strategies, recent developments, SWOT analysis, business overview, and market Trend from the year 2018-2022. Psychedelic Therapeutics Companies such as Celon Pharma Sa, Maps Public Benefit, Mindmed, Janssen Pharmaceuticals, Ix Biopharma Ltd, Jazz Pharmaceutical, Avadel, Pharmaceuticals Plc, Neurorx Inc, Douglas Pharmaceuticals Limited, The Emmes, Company Llc, Caamtech, Compass Pathways Plc, Eleusis Benefit Corporation, Awakn Life Sciences Inc, Psilera Bioscience, Braxia Scientific Corp, Mindset Pharma, Betterlife Pharma, Cybin, Cb Therapeutics, Numinus Wellness, Mydecine Innovations Group, Optimi Health, Pharmather, Field Trip Health, Atai Life Sciences, Gh Research, Seelos Therapeutics, Small Pharma, Bright Minds Biosciences Incannex Health, Psybio Therapeutics, Universal Ibogaine, Levitee Labs, Mind Cure Health, Novamind, Clearmind Medicine, Mynd Life Science, Wesana Health, Psyched Wellness, Havn Life Sciences, Tryp Therapeutics, Psyence Group, Silo Pharma, Core One Labs, M2Bio Sciences, Neonmind Biosciences, Delic Corp, Nova Mentis Life Science, Beckley Psytech, Delix Therapeutics, Diamond Therapeutics, Tactogen, Psygen Labs Inc, Bexson Biomedical, Eleusis Biotech, Psilera Biosceince, Octarine Bio, Heading Health, Maps Public Benefit Corporation (Pbc), Aphrodite Health, Terran Biosciences, Mycrodose Therapeutics, Reset Pharma, Clerkenwell Health, Alvarius Pharmaceuticals, Ceruvia Lifesciences are part of the final deliverable document along with the same we can provide data for 2nd, 3rd, start-up level companies data and strategies as well . This will help you to understand the competitive analysis of the market and how other players are performing in the market. This detailed competitive analysis will help you to strategize your business accordingly and will keep you one step ahead. A quantitative and qualitative analysis of the main players in the Psychedelic Therapeutics market is introduced, from the perspective of sales, revenue and price.
    Which segments are covered under Psychedelic Therapeutics market segments analysis?
    Under Psychedelic Therapeutics market segments analysis Type, Origin of Psychedelic Substance Target Therapeutic Area. It provides detailed insights on each type and application. Further, it provides which sub-segment is dominating the Psychedelic Therapeutics market along with its reason. Additionally, the Psychedelic Therapeutics market report will help you to analyze which sub-segment is fastest-growing during the forecast period.
    What has been the impact of COVID-19 on the Psychedelic Therapeutics market?
    After the analysis of the complete market, the report has provided how the COVID-19 pandemic has affected the market. All the parameters have covered the overall impact of COVID -19 on the market value, market trend & growth of the market, and how the major players in the particular market are adopting these changes. This will help you to understand the overall optimistic, pessimistic, and neutral effects of the coronavirus pandemic on the Psychedelic Therapeutics market.
    How the Psychedelic Therapeutics market performed till 2023 and how will it perform in the following years?
    The Psychedelic Therapeutics market has been analyzed thoroughly and has estimated the parameters which have affected the market in the historical period as well as how the market is going to perform in the following years. This will provide a complete market scenario and help you to strategize your next move accordingly to the Psychedelic Therapeutics market Share.
    Which region is expected to hold the highest market share in the Psychedelic Therapeutics market?
    The report gives an exhaustive investigation of the Psychedelic Therapeutics market at country & regional levels, and provides an analysis of the industry trends in each of the regions, from sales, revenue, and consumption. It will help you to understand which region is dominating the market and is expected to grow significantly in the following years. The regional analysis will help you in strategizing the expansion of business.
    What are the parameters used to analyze market position?
    Psychedelic Therapeutics market report has provided PESTEL and Porter analysis to provide insightful information regarding the market scenario. It also provides market attractiveness analysis with an acknowledgment of various factors within the market, including growth rate and market size, as well as outside factors such as access to raw materials, competition, and industry capacity.
    How to order Full Report or Sample pages of the Psychedelic Therapeutics market?
    The sample report for the Psychedelic Therapeutics Market can be obtained on demand from the website. Also, the 24*7 chat support & direct call services are provided to procure the sample report.

    What is included in the Psychedelic Therapeutics Market Report Access?
    • Measures to Explore Untapped Market
    • Understanding Market Dynamics
    • Understanding Changing Economics
    • Competitors Market Share
    • Global/Region/Country Level Analysis
    • Identify Upcoming End Use Industries
    • Global Price Trend Analysis
    • Value Chain Analysis
    • Customer Sentiment/Need Analysis
    • Identification of Key Growth Segments
    • Industry Upstream and Downstream Analysis
    • Raw Material Sourcing and Cost Analysis
    • Identify Key Customers Across Globe
    • Concept Development and Market Testing
    • Merger-Acquisition Strategy
    Reasons to Purchase the Psychedelic Therapeutics Market Report 2023 (Global Edition)?
    • The research study and report are been made exclusively for an institution or person who is strategizing to build a business or strategically wants to expand certain portfolio.
    • This report will help in analyzing complete market scenario across the globe who wish to expand their current business or is willing to invest in some profitable sector.
    • This report will prove beneficial for person or an organization who wish to be updated regarding their business environment, consumers’ behaviour, and their requirements. The environment is constantly changing, and in such scenario, this report will help in understanding market parameters through 360-degree view.
    • The report is thus ideal for KOL, CEO's, CFO's, directors, and others. It is also helpful to senior executives, business development managers, marketing managers, and consultants. Furthermore, government bodies, agencies and other kind of organizations can also leverage our report to understand market.
    Objective of Publishing Psychedelic Therapeutics Market Report 2023
    • Our objective for the Psychedelic Therapeutics market is to help in making imperative business decisions, securing investments, determining new business opportunities in the market. Further, the report helps to analyze overall marketing needs of customers, and avoid business failures.
    • To know the potential market size and growth rate before launching a new product line. The report in a way helps in designing R&D budget wisely by estimating maximum total profit.
    • To identify the Psychedelic Therapeutics market dynamics, industrial insights, and economic progression for critical information about the market conditions and specific business landscape.
    • To assess the overall competitive landscape of a particular business sector and to provide complete analysis in regards with various external factors impacting the market growth.
    • To create a strong foundation for building a strategy and foster insight into market conditions so that market players can make better business decisions. Besides, we aim to provide a complete portfolio of the major players involved the market.
    • To define the scope which will further help in creating new products that will surpass the gap between current offerings and customers’ needs.

    • To help in revealing significant clues concerning buying habits, regional culture, lifestyle, and population density that plays an integral role in shaping market behavior.
    • To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the total market.

    USPs and Service Differentiators
    • Competitors Analysis: We provide data from the supplier side covering key details such as market share split among 1st tier, 2nd tier, and 3rd tier, Emerging Players, and Start-Ups. (whereas most of our competitors published data for top-tier companies)
    • We provide market revenue share not only for Public listed companies but also the privately listed companies.
    • Country Analysis: The Country level market split analysis is part of the report hence the data granularity is provided.
    • We have been closely working with the Top 500 Fortune businesses, our clientele spanning 20+ industries. Our clientele is a mix of investors, manufacturers, end-users, distributors, etc. With our data subscription model (Athenaeum) 70% of clients have already subscribed/purchased reports for multiple years which helped us achieve unbelievable client retention statistics.
    • Product + Service: In terms of the product we deliver the report access (PDF+ PPT+ EXCEL+ Cloud+ POWER BI) whereas in terms of service; we provide data support where a dedicated research analyst will be assigned and add-on benefits. (Whereas most of our competitors believe only in delivering the data/report and service and support remain questionable.)
    • Credibility and Data Accuracy: We deliver accuracy close to 90-95% with the help of our in-house research team, freelancer, and industry expert network, sources present worldwide. This Data is backed up by strong What are our clients saying about our services.

    Read more

    We have listed the discounted pricing including Tax/es. Please kindly note, report pricing and data inclusion depends upon the selection of the report edition + user license. Hence, please kindly choose an appropriate user license depending upon the number of users or employees are going to utilize the report data or the as per the need of the data/consultation services. To know more contact us.

    Report Price (incl tax)

    The Global Report Edition and the respective table of content have been mentioned on the same page please refer the following link along with that incase you wanted further granular level data you should choose add-on report edition such as regional as well as country edition from below incase you are only interested into region specific or country specific the below options will more suitable for you

    Global Report Edition

    The regional report edition will help you get the data specific to the to selected region from the drop down.

    Region Specific Report Edition

    The country specific report edition and the respective table of content will be delivered to you as per your enquiry or you can refer the following link for the same.

    Country Specific Report Edition

    Compare User Licenses
    American Express Maestro Payment Master Card PayPal Visa Wire Transfer

    We have listed the discounted pricing including Tax/es. Please kindly note, report pricing and data inclusion depends upon the selection of the report edition + user license. Hence, please kindly choose an appropriate user license depending upon the number of users or employees are going to utilize the report data or the as per the need of the data/consultation services. To know more contact us.

    Report Price (incl tax)

    The Global Report Edition and the respective table of content have been mentioned on the same page please refer the following link along with that incase you wanted further granular level data you should choose add-on report edition such as regional as well as country edition from below incase you are only interested into region specific or country specific the below options will more suitable for you

    Global Report Edition

    The regional report edition will help you get the data specific to the to selected region from the drop down.

    Region Specific Report Edition

    The country specific report edition and the respective table of content will be delivered to you as per your enquiry or you can refer the following link for the same.

    Country Specific Report Edition

    Compare User Licenses
    American Express Maestro Payment Master Card PayPal Visa Wire Transfer
    logo-img
    +1 312-376-8303
    logo-img
    +44 208-144-9523
    info@cognitivemarketresearch.com

    How to Purchase the Full Report Access of Psychedelic Therapeutics Market Report 2023

    We have listed the discounted pricing including Tax/es. Please kindly note, report pricing and data inclusion depends upon selection of the report edition + user license. Hence, please kindly choose an appropriate user license depending upon the number of users or employees are going to utilize the report data or the as per the need of the data/consulation services. To know more contact us.

    a

    Student User License (PDF File): This license allows student to gain the access of the report at an exceptionally discointed price, Company profiles, Company Market Share will not be the part of deliverable report (Since this a confidential data hence respective chapters will not be shared with student/s and respective user license selection). To know more, email us.

    Student User License

    Data Pack : This is Quantitative Data (Excel Sheet) which presents Numeric Data, Graphs and Charts which can help to easily access the complete numerical data shared in our report. without any additional cost)

    Data Pack

    Single User License (PDF File): The purchase of a 'Single User License' grants access to a specific report for one person only and must not be shared with other employees within the same company. know more and compare USer license Options

    Single User

    Multi or Team User License (PDF File): (2 to 10 persons/employees) | The purchase of a 'Multi User License’ grants access to a specific report for a team of two to five users only within the same department or within the same company.

    Multi/Team User

    Corporate User License (PDF File): Unlimited User/Employees) | The purchase of a 'Corporate License’ grants access to a specific report to whole company and its wide audience. This includes subsidiary companies or other companies within a group of companies.

    Corporate User

    Athenaeum Subscription

    Athenaeum Subscription

    Report format can be PDF encrypted file, PPT, Excel, Online copy, Power Bi etc.

    Access

    Report format can be PDF encrypted file, PPT, Excel, Online copy, Power Bi etc.

    Access    		 Student Report Edition Excel Sheet PDF + Excel File PDF + Excel File + Cloud PDF + Excel + PPT + BI + Cloud + User Dashboard Access to Psychedelic Therapeutics DATABASE + Other Relevent Markets
     

    Number of users who can utilize the report data

    User Access

    Number of users who can utilize the report data

    User Access    		 Restricted Print, Copy, Paste & Download (Paid Download) Restricted Print, Copy, Paste & Download (Paid Download) Limited to 1 User Limited to Team Unlimited Users Unlimited Users
     

    We update our reports on the basis of either Quarterly Updates or on Client's Request

    Future Updates

    We update our reports on the basis of either Quarterly Updates or on Client's Request

    Future Updates    		 Paid Paid Paid Paid Free (3 Years Validity) Unlimited Validity
     

    This report is available for Quarterly Updates or on Client's Request, we suggest please kindly purchase Corporate User License

    Quarterly Updates

    This report is available for Quarterly Updates or on Client's Request, we suggest please kindly purchase Corporate User License

    Quarterly Updates    		 X X X X Free Quarterly Industry Update Free Quarterly Industry Update
     

    You can subscribe to either report or the whole industry. Our sales execute will guide you more regarding this option

    Subscription

    You can subscribe to either report or the whole industry. Our sales execute will guide you more regarding this option

    Subscription    		 NA $945.00 $945.00 $945.00 Free Unlimted
     

    You can customize the report user license according to your requirements.

    Add Ons

    You can customize the report user license according to your requirements.

    Add Ons    		 ✔ ✔ ✔ ✔ ✔ ✔
     

    You can Upgrade the report user license according to your requirements.

    License Upgrade

    You can Upgrade the report user license according to your requirements.

    License Upgrade    		 ✔ ✔ ✔ ✔ ✔ ✔

    You can print the report copy with additional charges. we suggest please kindly purchase Corporate User License for unlimited report print copies.

    Print Access

    You can print the report copy with additional charges. we suggest please kindly purchase Corporate User License for unlimited report print copies.

    Print Access    		 NA Free Free Free Free Unlimted

    Data Pack : This is Quantitative Data (Excel Sheet) which presents Numeric Data, Graphs and Charts which can help to easily access the complete numerical data shared in our report. without any additional cost)

    Data Pack

    This is a QUANTITATIVE DATA only, which includes but is not restricted to numeric data, tables, and charts.

    Data Pack (Add-On)    		 $645.00 USD Included Included Included Included Unlimted
    $945.00
    or Request Demo
    $1,845.00
    or Request Data Pack Sample
    $2,445.00
    or Request Report Sample
    $4,545.00
    or Request Report Sample
    $6,845.00
    or Request Report Sample
    or Request Demo
    NEED ASSISTANCE?
    WRITE US
    CALL US
    BOOK APPOINTMENT
    WRITE AN EMAIL
    info@cognitivemarketresearch.com
    sales@cognitivemarketresearch.com
    admin@cognitivemarketresearch.com
    CALL US
    USA: (+1) 312-376-8303
    Europe and UK: (+44) 20-8144-9523
    Asia Pacific: (+852) 81930785